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OBJECTIVES 
 
This study intended to assess the prevalence of Mitral Regurgitation in patients of acute ST 
elevation Myocardial Infarction (STEMI) during index hospitalization and during 1 month 
follow up along with 3D EF assessment. 
 
 
 
METHODS 
 
119 consecutive patients with STEMI were assessed for mitral regurgitation using various 
quantitative echocardiographic parameters like jet width, vena contracta and PISA during index 
hospitalization as well as during 1 month follow up. Left ventricular ejection fraction was 
assessed by both Simpson’s method as well as 3D echocardiography. All continuous variables 
are expressed as mean ± SD and categorical variables as number (percentages). Independent 
samples T test was used for comparative analysis of two continuous variables. Comparison of 
categorical variables was done using Chi square test. Pearson correlation coefficient was used to 
analyze the correlation between two continuous variables. 
 
 
RESULTS 
 
STEMI patients have 22.7% prevalence of MR at onset, which is more likely in older age group, 
diabetics and IWMI patients and independent of gender and left ventricle systolic dysfunction. 
Most commonly, ischaemic MR is of milder severity at onset which tends to persist in 15.7% of 
patients during follow up. Some patients may develop new MR later on depending on the LV 
remodeling. Modalities of revascularization doesn’t influence the course of Mitral Regurgitation 
in short term follow up.2D EF estimation with a properly acquired good image is comparable to 
more precise 3D EF in STEMI patients. 
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INTRODUCTION 
MR is a frequent complication of coronary artery disease. It was often under-rated 
because it is clinically silent, but with the use of echocardiography this 
complication is observed between 15%-20% after a myocardial infarction.1 When 
compared with patients without MR, the patients with acute myocardial infarction 
and mitral regurgitation are older, more often in female and  frequently have a 
history of previous ischaemic heart disease.2 Its presence and degree have major 
prognostic implications and underscore the importance of its detection and 
quantification. Ischaemic mitral regurgitation can independently predict 
cardiovascular death with a relative risk of 2.3 In a community trial, Bursi et al 
found that mitral regurgitation predicted heart failure as well as mortality among 1 
month survivors independent of age, gender, ejection fraction, and Killip Class.4 
Even mild MR was shown to increase the mortality in SAVE trial (Survival and 
Ventricular Enlargement) 3 hence, detection and quantification of MR is crucial. 
                                         MR can be estimated by different techniques on 
echocardiography. Color flow imaging allows an easy visualization of MR, but 
was found to overestimate the MR.5 Mccully et al demonstrated that the same jet 
area corresponds to smaller regurgitant volumes in functional MR as compared to 
organic MR.5 Doppler echocardiography allows accurate assessment of regurgitant 
volume and effective regurgitant orifice and thus provide the tools to reliably 
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evaluate the prognosis and mechanism. Doppler methods are simple, fast, 
reproducible and proven to be more reliable bur sparsely applied in routine clinical 
evaluation. Current guidelines advocate quantification of MR by the measurement 
of vena contracta and proximal isovelocity surface area (PISA), the most 
recommended quantitative approach whenever feasible. The semi-quantitative 
evaluation should be abandoned.6 
                                      Echocardiography is the most common method to assess 
left ventricular systolic function. It can efficiently predict the outcome and help in 
determining the treatment modalities like CRT-D implantation etc. Routine 2D EF 
measurement has several limitations in AMI patients due to problems of 
foreshortening and  geometric assumptions.3D echo LVEF is much more accurate 
especially in presence of regional wall-motion abnormalities as it does not have 
geometric assumptions and is found to have  comparable with present day ‘‘gold 
standard’’ for systolic function , cardiac MRI .7 It can automatically calculate 
ejection fraction and left ventricular mass using the automated software’s, and is 
therefore more reproducible. It is several folds accurate as compared to 
conventional echo. 
         As there is no data for prevalence of Mitral Regurgitation in Indian 
population, this study was undertaken. We evaluated the prevalence and degree of 
Mitral Regurgitation in the acute phase and after 1 month of STEMI. 
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AIMS AND OBJECTIVES 
 
PRIMARY AIM 
a. To study the following parameters in  Acute ST Elevation Myocardial 
Infarction[STEMI] patients   
i. Prevalence of mitral regurgitation[MR] by echocardiography in acute 
STEMI and during 1 month follow up 
ii. 3D-EF(ejection fraction) assessment 
 
SECONDARY AIM 
a. Correlation of 2D-EF, 3D-EF and MR in STEMI patients 
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                                  REVIEW OF THE LITERATURE 
 
INTRODUCTION 
Mitral regurgitation (MR) is defined as systolic retrograde flow from left ventricle 
(LV) to left atrium (LA) because of pressure gradient between the two chambers. 8 
The term ischaemic MR does not necessarily imply the presence of true 
myocardial ischemia, it is in fact an abridgment, characterizing a clinical situation 
corresponding to chronic coronary artery disease with frequently a prior history of 
one or more myocardial infarctions leading to progressive global or regional 
pathological LV remodelling, usually in the absence of reversible ischaemia.9 
                                        Ischemic MR is a type of secondary/functional MR due to 
coronary artery disease. Secondary MR is defined as functional MR, due to LV 
remodelling by idiopathic cardiomyopathy or coronary artery disease.8, 10 It is 
important to distinguish between primary MR due to organic disease of one or 
more components of the mitral valve apparatus and secondary MR which is not a 
valve disease, but represents the valvular consequences of a LV disease. There are 
however limitations in both terms: functional and ischemic. Indeed, recent studies 
have demonstrated evidence of structural changes in the mitral leaflets in response 
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to tethering on them by LV pathological remodelling. The leaflet adaptation 
includes enlargement and increased stiffness.11 
 
PREVALENCE 
MR is a frequent accompaniment of ischaemic heart disease. Clinical presentation 
is variable from silent to severe MR presenting with hemodynamic instability. It 
may be an incidental finding on echocardiography  or catheterization .3  Its 
importance was often underscored because of low murmur intensity but with the 
use of echocardiography, MR is observed between 15%-20%  of patients with 
acute myocardial infarction.1Different investigators have found variable incidence 
of MR in acute MI with the help of different imaging modalities.Lehmann et al 
found 13 % incidence of mitral regurgitation early in the course of acute 
myocardial infarction with the help of contrast left ventriculography.2 Tcheng et al 
reported incidence of post-infarction  mitral regurgitation  was to be  17.9% of 
patients within hours of infarction.12  Indeed, when it is sought by doppler, MR has 
been reported to occur in up to 39% of patients with MI. 13,14  With the recent 
advances in non-invasive doppler echocardiography ,it is possible to accurately 
assess the regurgitant volume and effective regurgitant orifice. Old age, diabetes, 
past history of MI, severe CAD are more frequently associated with STEMI with 
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MR than patients with STEMI without MR.2, 12, 15 Its presence and degree have 
major prognostic implications and mandates its detection and quantification. 
 
PATHOPHYSIOLOGY 
Normal mitral valve function depends on perfect delicate interplay between the 
mitral leaflets, the subvalvular- apparatus (which includes: chordae tendinae and 
papillary muscle), the mitral annulus, and the left ventricle. Pathophysiology of 
ischemic MR is perplexing. Myocardial damage and LV dysfunction usually 
precedes MR. Ischemic MR is characterized by normal leaflets and subvalvular 
apparatus and occurs due to restricted motion of the leaflets. According to the 
Carpentier’s classification, ischaemic mitral regurgitation is classified as type 3. 16 
Given below is the classification based on motion of leaflet in relation to the mitral 
annular plane (figure 1) 
1: normal leaflet motion. Perforation of the leaflet due to traumatic injury or 
endocarditits, or annular dilatation, which may cause left ventricular disease, is the 
cause of MR in type1. 
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 2: excessive leaflet mobility accompanied by displacement of the free edge of one 
or both leaflets beyond the mitral annular plane into the left atrium, degenerative 
cardiac diseases may cause leaflet prolapse. 
3:  leaflet restriction.  It is further subclassified into 2 varieties: 
 3a, where the restriction occurs  throughout the cardiac cycle, i.e. both  in systole 
and diastole due to shortening of the chordae and/or leaflet thickening such as in 
rheumatic disease,  
 3b, where the leaflet restriction is seen in systole only (usually the result of 
regional wall motion abnormalities seen in ischaemic mitral regurgitation).16 
 
 
 
Figure 1: Carpentier’s functional classification of Mitral Regurtitation17 
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Mitral Leaflet closure is mainly an intricate interplay between the forces of 
tethering and ventricular forces (figure 2, 3). Increase in tethering forces will not 
allow adequate closure of the mitral leaflets.8, 18 The most frequent pattern seen is 
posterior infarction, more commonly trans mural, leading to local left ventricular 
pathological remodelling and thereby contributing to posterior, apical and lateral 
displacement of the posterior papillary muscle. As the papillary muscle extends 
non-extensible chordate to both the leaflets, its displacement results in a more 
apical tethering of the leaflets and their coaptation point, and a characteristic 
deformity of the anterior leaflet which is described as the ‘seagull sign’.8, 19 The 
tethering process produces the shape like that of a tent between the annular plane 
and the displaced leaflets. The tenting volume closely estimates the  regurgitant 
orifice area.8,20  Tenting area is asymmetric in case of posterior infarction and 
regional remodelling, predominates on the posterior leaflet close to the medial 
commissure. It is accompanied by decreased mobility of the posterior leaflet. In 
another subgroup  of patients with previous anterior infarction  or both anterior and 
posterior infarctions, LV dilatation is more global, LV is more spherical, both 
papillary muscles are displaced, the tenting area is symmetric, the regurgitant jet is 
central and  the contribution of annular dilatation and flattening is more important. 
Second important determinant is decrease in  ventricular closing forces,  includes 
altered systolic annular contraction ,LV dysfunction ,reduced synchronicity 
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between the two papillary muscles and global LV dyssynchrony, especially in 
basal segments.8Factors aggravating the mitral regurgitation  are  dilatation of the 
mitral annulus and the decrease in systolic annular contraction, but isolated annular 
dilatation does not create functional mitral regurgitation.18 
 
 
 
Figure 2: Left figure: Normal coaptation is seen. Right figure: tethering of leaflet 
due to papillary muscle displacement and annular dilatation   
AO, aorta; Inf PM, inferior papillary muscle; LA, left atrium; LV, left ventricle; 
MR, mitral regurgitation.  
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(Reproduced from Levine RA, Hung J, Otsuji Y, et al. Mechanistic insights into 
functional mitral regurgitation.  Curr  Cardiol Rep 2002; 4:125–9) 
 
Occasionally, leaflet prolapse can occur as a result of fibrotic elongation of 
papillary muscle which may be followed by an event such as myocardial infarction 
and this can result in MR. (Carpenters’ Type 2). 
The consequences of MR depend on the following underlying factors 
a. Severity of regurgitation 
b. LA compliance  
c. LV-LA gradient (the driving force) 
d. Duration of the lesion 
Acute MR can occur secondary to two rare causes: rupture of a papillary muscles 
resulting from acute myocardial infarction and transient active ischemia leading to 
true ischemic MR. The rupture of a papillary muscle, more often in the location of 
head of the postero-medial papillary muscle, is a catastrophic complication of 
actual MI with a high mortality if emergency surgery is not done.8, 21 
In majority of patients with chronic ischemic MR complicating left ventricular 
dysfunction and heart failure, LA is enlarged and has a greater compliance with 
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low driving force. The volume overload resulting from  MR contributes to a 
vicious cycle : the more remodelling of  left ventricle, the more severe MR begets 
MR, so greater the severity of MR, larger the volume overload on LV which 
finally leads to LV remodelling.LV becomes more and more dilated and spherical 
in accordance to laplace law, which further propentiates the MR. Despite a 
reduction in LV impedance, LV wall stress increases ,finally translating into LV 
dysfunction.22 Chronic ischaemic MR finally leads to development of pulmonary 
arterial hypertension. 
 Another important feature of ischaemic MR is its dynamicity. 23 The degree of 
MR is best quantified by the effective regurgitant orifice (ERO) area. 24 The 
regurgitation area keeps on changing throughout the systole due to dynamic 
changes in transmitral pressure, though it is of lesser  importance in mid-systole 
when compared to other phases of systole.25,26 ERO is load dependent, therefore 
affected by daily activities. Another evidence of the dynamicity of ischaemic MR  
is a reduction of regurgitant volume related to a reverse LV remodelling obtained 
by appropriate medical treatment. 27 Dynamic nature of MR can be very well 
appreciated during an exercise doppler echocardiogram.28 The degree of MR seen 
at rest is not related to exercise-induced changes in ERO area or regurtitant 
volume.29 Exercise-induced changes are quite variable in different individuals.  
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              ↑ tethering forces               ↓ Ventricular forces (left ventricle dysfunction) 
                                                      
                                                             Ischemic MR 
 
                LA Enlargement                                           ↑ Left Ventricular wall stress 
               AF, PAH                                                          left ventricle Remodelling 
                                                     (Annular dilation, papillary muscle displacement) 
 
Figure 3: Pathophysiology of Ischaemic MR 
In some individuals with moderate or severe MR at rest, a decrease in ERO area 
can be observed with exercise and usually results from contractile reserve of the 
LV, in particular of the postero-basal segment and/or a reduction in intra LV 
dyssynchrony.30 Around 30% of these patients develop an increase in the severity 
of regurgitation and in systolic pulmonary artery pressure during exercise. The 
degree of exercise-induced increase or decrease in MR relates to changes in valve   
deformation, LV remodelling and papillary muscles synchronicity. 
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DIAGNOSIS AND QUANTIFICATION 
Clinical examination in ischaemic MR may reveal a regurgitant murmur of low 
grade or may even be silent or inaudible .It is an insensitive method for ischaemic 
MR diagnosis due to subtle or near normal auscultatory findings in many patients. 
This can be explained from the fact that cardiac output is low, LV contractility is 
compromised and atrial pressure is high thereby they cause lower regurgitant 
volume, consequently low grade murmur in ischemic MR compared to organic 
MR. There is no correlation between intensity of murmur and severity of ischaemic 
MR. 
The diagnosis of ischaemic MR is usually made by using imaging modalities like 
doppler echocardiography. Doppler echocardiography is a useful tool in diagnosis 
and is superior to other techniques like contrast ventriculography. Importance of 
doppler echocardiography in routine clinical practice is undisputed. Clinically 
subtle findings like low intensity murmurs should always lead to a careful 
echocardiographic examination. 
Quantification of MR is also crucial. Echocardiography plays a key role not only in 
diagnosis of regurgitant lesion but also in the assessment of the mechanism and the 
severity of MR. It also has a role in determining treatment options as it helps in 
determining the feasibility of valve repair versus replacement.  
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Assessment of Mitral Regurgitation by echo can be (a) qualitative (b) quantitative.  
QUALITATIVE METHODS 
Colour flow imaging 
Colour flow imaging is the most widely used method to assess MR severity 
echocardiographically .32 This measurement is poorly reproducible and influenced 
by various factors. Though it allows an easy visualization of the regurgitation and 
frequency of MR, it has major limitations in assessing the severity of MR. 5, 33 It 
tends to overestimate the severity of regurgitation. It is generally assumed that with 
increasing MR, the size and extent of the regurgitant jet in LA is increased. Larger 
colour jets extending deep into LA represent greater severity of MR than small thin 
jets that appear just beyond the mitral leaflets. However, the jet size may be 
influenced by other factors such as technical and hemodynamic influences and 
therefore caution must be exercised in interpretation of jet severity based on jet 
size. For the same severity of MR , patients with increased LA pressure, enlarged 
LA or wall hugging eccentric jet  may show  smaller jets area when compared with 
normal LA pressure, size or with central jets.6 In acute MR, even centrally directed 
jets may be misleadingly small. Nevertheless, a large eccentric jet adhering, 
swirling and reaching the posterior wall of the LA favours significant MR and 
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smaller thin jets appearing just beyond the mitral leaflets usually is an indicator of 
mild MR. 
Continous Wave Doppler of MR jet 
Continuous wave doppler of mitral regurgitation jet is another qualitative 
parameter which is used to measure the severity of mitral regurgitation. The signal 
intensity (jet density) of the CW envelope of the mitral regurgitant jet can be used 
as a qualitative indicator to mitral regurgitation severity. A dense triangular mitral 
regurgitation signal with a full envelope indicates severe mitral regurgitation than a 
faint signal. Truncated (notch) envelope with a triangular contour and an early 
peak velocity (blunt) indicates elevated LA pressure or a prominent regurgitant 
pressure wave in the LA due to severe MR. In case of eccentric mitral 
regurgitation; it may be difficult to record the full CW envelope of the jet, while 
the density may be used as indicator for assessing the severity. 
SEMIQUANTITATIVE MEASURES 
The semi-quantitative evaluation of regurgitant jet area should not be used.6 It is 
recommended that these measures should only be used for diagnosing mitral 
regurgitation, and not to quantify the severity of MR. A more quantitative 
approach is recommended when more than a small central MR jet is seen. 
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Vena contracta width (VCW) 
The vena contracta is the narrowest portion of the MR jet downstream from the 
orifice; it reflects the effective orifice area.34-36 Whenever feasible measure the 
dimensions of vena contracta,  which can help in quantification of MR. Using a 
careful probe angulation and adapted Nyquist limit (colour Doppler scale) (40–70 
cm/s), the vena contracta is typically imaged in a view perpendicular to the 
commissural line (e.g. the parasternal long-axis or the apical four chamber view) to  
identify the neck or the  narrowest portion of the jet. This narrowest doppler colour 
sector scan can be coupled with the zoom mode to improve resolution and for more 
accurate measurement (Figure 4). It is recommended that if possible averaged 
measurements over at least three beats should be taken and measurements should 
be taken from two orthogonal planes. A vena contracta, < 3 mm is considered as an 
indicator of mild MR whereas a width ≥7 mm defines severe Mitral Regurgitation, 
values in between 3 to 7 mm are ambiguous and need further confirmation by a 
more quantitative method.6 
The concept of vena contracta is based on the assumption that the regurgitation 
orifice is almost circular, this assumption holds true in cases of organic MR but in 
functional MR the results may not be accurate as the orifice may be non circular 
and elongated along the mitral coaptation line. 37, 38 Thus, it could look narrow in 
four-chamber view and broad in two-chamber view. Conventional 2D colour 
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Doppler imaging does not provide appropriate orientation of 2D scan planes to 
obtain an accurate cross-sectional view of the vena contracta. The vena contracta 
can be classically well identified in both central and eccentric jets. In case of 
multiple MR jets, the respective widths of the vena contracta are not additive. Such 
characteristics may be better appreciated and measured on 3D echocardiography. 
In cases of functional MR, a mean vena contracta width (four- and two chamber 
views) has been shown to be better correlated with calculation done using  the 3D 
vena contracta.41 3D echo assessment of the vena contracta is not used routinely 
and currently it is used for research purposes. 
A mean value >8 mm on 2D echo has been reported to define severe MR for all 
aetiologies of MR including functional MR, though it needs confirmation in further 
studies.39 
Pulmonary venous flow Doppler 
It is an additional parameter for evaluation of MR severity. Normally, if there is no 
diastolic dysfunction in venous flow Doppler we get a positive systolic wave (S) 
which is followed by a smaller diastolic wave (D). As the severity of MR 
increases, there is a blunting of the S wave velocity. Systolic blunting or systolic 
flow reversal will be seen in moderate and severe MR respectively. 
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Figure 4. Measurement of Vena contracta width in Mitral Regurtiation. 
QUANTITATIVE METHODS 
Doppler volumetric method  
Doppler volumetric method can calculate regurgitant volume by finding the 
difference between measured mitral and aortic stroke volume.43.It can be inferred 
using 2D echocardiograph by calculation of LVEDV and LVESV which are 
calculated using biplane method of disks. 42 Same jet areas correspond to smaller 
RVol in ischemic MR than in organic mitral regurgitation. However, this method is 
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cumbersome and time consuming. It is not recommended as first line investigation 
for quantification of regurgitant volume.  
 Flow Convergence Method 
Flow-convergence method is the most frequently quantitative method for 
estimation of MR in current practice.44It is based on law of conservation of flow; 
its basis lies in the modified form of continuity equation. It enables the 
measurement of ERO area and regurgitant volume with precision.45 As the flow 
convergence is proximal to the regurgitant orifice it forms the basis of analysis.46 
The apical four-chamber view is classically recommended for enabling good 
visualization of the proximal isovelocity surface area (figure 5). However, in 
anterior mitral valve prolapse the calculation of PISA should be done in the 
parasternal long- or short-axis view. By lowering the image depth and reducing the 
Nyquist limit to 15–40 cm/s, flow velocity at a hemispheric surface proximal to 
regurgitant orifice can be determined.6 The radius of the PISA is measured at mid-
systole using the first aliasing. Regurgitant volume (R Vol) and effective 
regurgitant orifice area (EROA) are obtained using the standard formula.  
 
Regurtitant flow = 2 Π (radius of the flow convergence) 2 x aliasing velocity 
ERO is the ratio of regurgitant flow /peak mitral regurgitant velocity 
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Regurtitant volume (RVol) is calculated as product of ERO and MR TVI. 
Qualitatively, the presence of flow convergence at a Nyquist limit of 50–60 cm/s is 
an indicator to the presence of significant MR.6 
Grading of organic MR 6 
                                          Mild                          Moderate                              Severe 
EROA (mm2)                    <20                         20–29; 30–39                           ≥40 
R Vol (mL)                         <30                        30–44; 45–59                             ≥60 
Moderate regurgitation group can be further classified into ‘mild-to-moderate’ 
(EROA of 20–29 mm2, R Vol of 30–44 mL) and ‘moderate-to-severe’ (EROA of 
30–39 mm2 or R Vol of 45–59 mL). In ischaemic MR, the thresholds of severity, 
which are of prognostic value, are 20 mm2 and 30 mL, respectively.47 EROA is the 
most robust parameter as it represents a marker of lesion severity. A large EROA 
can lead to large regurgitant kinetic energy (large R Vol) as well as to potential 
energy, with low R Vol but high LA pressure. 
                                                                        
                        Figure 5: Ischaemic MR Grading
This method is simple, fast, 
investigators.46; 49It precisely calculates the 
overload induced by MR, and the effective regurgitant orifice (ERO), which 
delineates the severity of anatomic lesion. 
Low Risk
EROA<20mm2 RVol<30ml
21 
 (6, 48)
 
and reproducible and has been validated by
RVol, which indicates the volume 
 
Ischemic MR
High Risk
EROA>20mm2 RVol>30ml
 
 multiple 
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Figure 5. Determination of radius of proximal isovelocity surface area (PISA) in 
ischaemic Mitral Regurgitation. 
There are several limitations of the proximal isovelocity surface area (PISA) 
approach. 8,46 First, the PISA radius changes during systole is larger in early and 
late systole, and smaller in midsystole when the LV pressure is maximal.50 Ideally, 
the PISA radius should not be measured at only one time point, but averaged 
through systole. Second, for an accurate measurement, the flow convergence 
should be hemispheric. In cases of functional MR, the flow convergence—a three-
dimensional structure—is frequently hemielliptic (Fig 6), implying an 
underestimated calculation of ERO and regurgitant volume, particularly when the 
PISA radius 
 
23 
ratio of long-axis length to short-axis length of the 3D regurgitant orifice is >1.5. 38, 
51-52 
Third, multiple jets can be present; the addition of several flow-convergence 
regions has not been validated. Fourth, it is more accurate for central jet. It may not 
hold for eccentric jets, several jets, or complex or elliptical regurgitant orifices. 
Practically, the geometry of the PISA varies based on the shape of the orifice and 
mitral valve leaflets surrounding the orifice. 
 
 
Figure 6: 3Dimensional shape of the convergence flow in (a) functional MR (b) 
organic MR 
(Reproduced from EHJ guidelines for the assessment of the valvular regurgitation 
2010) 
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Thus, practically, the most reliable calculation of regurgitant volume and ERO area 
is the averaging of the quantitative doppler and the PISA methods .However, this 
approach is time consuming.8 
Invasive assessment 
Mitral regurgitation could be assessed by invasive ventriculography. Some schools 
of thought have considered Left ventriculography as the reference methodology for 
assessment of mitral regurgitation. However this method of grading of MR is also 
subject to limitations and cannot thereby be considered gold standard because of 
influence of loading conditions affecting the MR severity. 
Comparatively, Quantitative Doppler echocardiography is non invasive and also 
provides more objective data for grading and prognostic information about 
regurgitation than ventriculogram.53 
PROGNOSIS 
The presence of ischaemic MR is an important indicator for long term morbidity as 
well as mortality. It is an independent risk factor for the same. The presence of 
ischaemic MR may result from acute infarction resulting in regional left ventricular 
dilation and consequent loss of contractile mechanism or in some instances it may 
be a previously existing lesion which went undiagnosed. Several studies have  
clearly shown that ischaemic mitral regurgitation can predict cardiovascular 
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mortality independently.2-4,8, 12, 54 Relative risk was found to be quite variable 
ranging from 1.48 - 7.5.8  Worse long term prognosis was seen in patients 
presenting with non ST elevation myocardial infarction .55 A community based 
study has also confirmed the prognostic importance of ischaemic MR among one 
month survivors of MI: its presence is associated with a three-fold increase in the 
risk of heart failure and a 1.6-fold increased risk of death at 5-year follow-up, 
independent of LV ejection fraction, Killip class, age and gender.4,8 Barzilai et al 
found that AMI patients with a murmur suggestive of MR had a 12-month 
mortality of 36% compared with 15% for patients without an MR murmur. 
56SAVE study investigators also showed that mild MR was associated with high 
mortality. Greater the severity of mitral regurgitation, worser was the prognosis.48 
Even uncorrected mild MR, as well as moderate to severe ischaemic MR is found 
to be associated with higher mortality on long term. However, the severity of 
ischaemic MR tends to follow the severity of the LV dysfunction causing the MR; 
the worse the MR, the worse the LV functions. Till date, there are no studies to 
prove that ischaemic MR is a predictor of long term prognosis irrespective of 
severity of LV dysfunction present.8 No studies have proved that correction of 
mitral regurgitation will mitigates the long term mortality independent of left 
ventricular systolic dysfunction8 
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Though small case series has shown that coronary revascularisation in acute MI 
has reduced the severity of MR in selected patients, it tend to  persist in > 50% of 
patients of MI on follow up.12 Therefore, even coronary revascularisation may not 
halt its progression during long term. 
 Prognosis is also found to be related to the dynamicity of component of ischaemic 
mitral regurgitation. A 5 fold increase in the relative risk of death with an exercise-
induced increase of ≥13 mm2 of the ERO area was found.8, 57 It is the best 
predictor of hospitalisation and cardiovascular morbidity as compared to severity 
of mitral regurgitation at rest. Its deleritious effects are related to several factors 
like sudden increase in R Vol (regurgitant volume) and with rapid QRS widening 
due to increases in ventricular wall stress leading to worsening LV dyssynchrony.58  
  In patients with LV systolic dysfunction, acute pulmonary oedema which may 
develop due to sudden worsening of dynamic MR leading to acute increase in left 
atrial pressures.8, 59 Greater exercise-induced regurgitant volume and systolic 
pulmonary arterial pressure may cause exertional dyspnea.60 Around 20% may 
have an improvement in the severity of ischaemic mitral regurgitation during 
exercise, who have a favourable long term prognosis. 57 This is thought to happen 
in patients with contractile reserve in posterior segment.29 
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MANAGEMENT 
Numerous treatment options have been proposed but the treatment of ischaemic 
mitral regurgitation still remains a complex issue and needs further research and 
trials to find an ideal treatment modality with long term benefits. In current clinical 
approach at most places ring annuloplasty is preferred treatment modality. 
However, long term benefits of this technique remains obscured as it has no role in 
correction of local alteration due to left ventricular remodelling. 
Medical Management 
Standard anti-failure medications such as angiotensin-converting enzyme (ACEI) 
inhibitor or ARBs if the ACEI is not well tolerated), aldosterone antagonist and 
beta-blockers .8, 61  It may help in alleviating the severity of mitral regurgitation by 
producing reverse  left ventricular remodeling.8, 62 
Cardiac resynchronization therapy 
Though biventricular pacing per se is not an treatment modality for ischaemic 
mitral regurgitation, it is an indication to consider CRT in patients of ischemic MR 
with reduced left ventricular ejection fraction ,functional class III or more even 
with medical treatment and ecg showing QRS of more than 120 ms.63 Cardiac 
resynchronization therapy resynchronize the papillary muscles and increase the 
closing force which helps in  immediate reduction in MR.8,64-65 There is  further  
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more reduction in the severity of MR in long term that is after few weeks or 
months as it plays a role in LV reverse remodelling, through a reduction in 
tethering .It can also reduce dynamic MR.66 Magnitude of  MR induced by exercise 
attenuate significantly in parallel to reverse Left Ventricular remodelling over a 
period of three months and result in improved cardiopulmonary performance.8, 67 
Despite a reduction in the severity of MR, residual MR frequently persists. 
Immediate recurrence of MR has been seen post withdrawal of CRT due to 
dyssynchronization of the papillary muscles leads to. 68-70 
Percutaneous coronary revascularization 
It may help in reducing the severity of mitral regurgitation at rest as well as during 
exertion in the subset where it is directly induced by ischaemia. .8 
Surgical Management 
Surgical approach for management of ischemic MR can only reduce its severity, 
not eliminate it completely. Coronary artery bypass grafting  by itself is regarded 
insufficient in  correction of MR. 71 Persistence of even little residual mitral 
regurgitation postoperatively has been shown to be associated with higher 
mortality 72 With the use of an undersized prosthetic (preferably two-sizes) ring 73, 
reduction in LV volume has been seen  and even a small increase in LV ejection 
fraction has been documented , 74 but the long-term benefits could not be 
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proved.75,76 Several studies have shown that long-term outcomes in terms of  
survival benefit or functional outcome  is  questionable by combined surgery. 75,77-
78
 In a recent randomized control trial it has been shown that mitral valve repair 
done along with  CABG was associated with improvement of  NYHA class, LVEF, 
and reduction in left ventricular diameter, left atrial size and PAP(pulmonary artery 
presence) .79It  was not powered enough to analyse the effect on mortality . To 
conclude it may be said that fixing some valves may help, but it is difficult to 
identify which ones.80 Recently published meta-analysis showed that mitral valve 
repair for ischaemic mitral regurgitation is associated with better survival 
compared with MVR (mitral valve replacement). 81 
The European Society of Cardiology guidelines recommend that patients with 
severe ischemic mitral regurgitation (ERO area ≥20 mm2) undergoing CABG 
should be treated by combined surgery (class I, level of evidence C). 8,82Mitral 
valve repair may be considered in symptomatic patients with severe mitral 
regurgitation who cannot be revascularized is questionable (class IIb).82 Mild 
mitral regurgitation should be managed conservatively. Due to the lacuna of well 
defined guidelines and evidence, the management of ischemic MR should be 
individualized. Assessment of myocardial viability, especially in region of 
posterior basal wall, inducible ischemia and the dynamic component of MR aids in 
decision making. Biphasic response or regional contractile reserve during stress 
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testing usually have exercise-induced reduction in mitral regurgitation, can be help 
decision making. Patients with exercise-induced increase in effective orifice area 
area ≥13 mm2 could be taken up for combined surgery. Severity of MR is always 
underestimated even with intra-operative TEE. Pharmacological measures like 
phenylepherine or rapid fluid challenge may be used to assess the ischaemic MR.83 
Parameters like grossly dilated left ventricle, multiple regurgitant jets , systolic 
sphericity index, wall motion score index, ESV( end-systolic volume), severe MR,  
>2.5 cm2 systolic tenting area, , large angle (≥45°) of the posterior leaflet, >1 cm 
distance between coaptation point and mitral annulus are recognized as predictors 
of bad outcome of procedures like mitral valve repair by annuloplasty .84-86 
Several adjunctive techniques have been proposed like chordal cutting, internal 
direct repositioning or external repositioning of the displaced papillary muscle. 8, 87 
However, they are not yet clinically approved for routine management of 
ischaemic mitral regurgitation. 
PERCUTANEOUS REAPIR 
Percutaneous edge-to-edge Alfieri procedure has been used for the treatment of 
MR due to either ischaemic or organic cause. In it, the central parts of both mitral 
leaflets are apposed producing a double orifice. 8, 88 Many researchers have 
developed the devices which can be delivered in coronary sinus and reduce the 
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severity of mitral regurgitation by pushing the PML forward.89-90 Long term effects 
of these devices needs to be studied. 
FORTHCOIMG THERAPIES 
Future targets like transplanting autologous myoblast has potential proven to cause 
localized LV reverse remodelling and appears to be a promising approach in 
decreasing ischaemic MR. More understanding of our concepts of leaflet 
adaptation in LV dysfunction can help us in developing potentially better therapies 
in future. 91 
3D EF Measurement in Myocardial Infarction 
                           Echocardiography is the most common method to assess left 
ventricular systolic function. It can efficiently predict the outcome and help in 
determining the treatment modalities like CRT-D implantation etc. Routine 2D EF 
measurement has several limitations in AMI patients due to problems of 
foreshortening and  geometric assumptions.3D echo LVEF is much more accurate 
especially in presence of regional wall-motion abnormalities as it does not have 
geometric assumptions and is found to have  comparable with present day ‘‘gold 
standard’’ cardiac MRI .(5) It can automatically calculate ejection fraction and left 
ventricular mass using the automated softwares, and is therefore more 
reproducible. It is up to 3 times more accurate than 2DE LVEF.7  
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Figure 7.Measurement of 3D EF in echocardiography through Q lab analysis 
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DESIGN AND METHODOLOGY 
Study Design: 
This is a single centre prospective observational study done in the department of 
Cardiology, Christian Medical College (CMCH), Vellore. 
                                                           SETTING 
Study was done in the Cardiology department of Christian Medical College and Hospital, 
a tertiary care hospital in South India.119 consecutive patients with STEMI were assessed 
for mitral regurgitation using various echocardiographic parameters. 
                                         STUDY PARTICIPITANTS 
 Inclusion criteria: 
All patients older than 18 yrs old, who sustained STEMI between September 2011 
to August 2012.  
Exclusion criteria: 
    Patients were excluded from the study if they had 
1.  Rheumatic heart disease  
2. Persistent arrythmias 
3. Known coronary artery disease(CAD) 
4. Cardiogenic shock 
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5. Trivial MR 
Methods: 
1. Demographic and clinical profile of patients were collected were 
collected once they consented 
2. All patients underwent echo once they were stable during index 
admission. Mitral regurgitation quantified using jet width[vena 
contracta], jet area and proximal isovelocity surface area(PISA) ,if central 
jet is present 
3. Left ventricular ejection fraction  were assessed by both Simpson’s 
method as well as 3D echocardiography 
STATISTICAL ANALYSIS 
Statistical analysis was done using commercially available statistical software 
(‘IBM SPSS software version 15’, Illinois, Chicago). All continuous 
variables are expressed as mean ± SD and categorical variables are expressed 
as number (percentages). Independent samples T test was used for 
comparative analysis of two groups with a normally distributed continuous 
variables. Comparison of categorical variables was done using Chi square 
test. Pearson correlation coefficient was used to analyze the correlation 
between two continuous variables with a normal distribution. Comparative 
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analysis was performed by one way analysis of variance (ANOVA). A p 
value less than 0.05 was considered statistically significant for all test results. 
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RESULTS 
1. STUDY PROFILE AND BASELINE CHARACTERISTICS 
A total of 119 patients of STEMI were evaluated for ischaemic MR during the 
study period. Mean age of patients in the whole study population was 53.42 ± 
11.47 years. Majority patients (57.1%) were found to be in the age group of 40-59 
years, with least number was in >80 yrs (2.5%).10.9% patients were young, <40 
years having MI. Number of males outnumber within each group.Ratio of Males: 
Female is 96:23. 31.9%(38) of the patients has type 2 diabetes mellitus,98.3%(117)  
of patients had dyslipidemia, 37.8(45)  % of the patients had hypertension ,54.6% 
(65) were obese , 47.1%(56) were  current smoker and 13.4%(16) had positive 
family history of coronary artery disease(CAD). On an average all patients were 
had at least 2 risk factors. 
             Baseline characteristics of both groups with Anterior wall MI (AWMI) and 
Inferior wall MI (IWMI) were comparable without any significant statistical 
difference except baseline 2D EF, which was higher in IWMI group (table 1). 
Patients presenting with AWMI were having slightly higher proportion of 
hypertension, though it was statistically insignificant.     
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Characteristic AWMI IWMI p value 
Age 52.30±11.11 54.58±11.81 .281 
Male 47(78.3%) 49(83.1%) .515 
Female 13(21.7%) 10(16.9%) .515 
Diabetes 19(31.7%) 19(32.2%) .85 
Hypertension 27(45%) 18(30.5%) .103 
Smoking 29(48.3%) 27(45.8%) .779 
Dyslipidemia 59(98.3%) 58(98.3%) .990 
Obesity 35(58.3%) 30(53.1%) .293 
Positive Family 
History 
10(16.7%) 6(10.2%) .299 
Baseline 2D EF 44.94+7.5 50.7+7.4 .000(significant) 
Baseline 3D EF 45.42+8.5 46.96+8.6 .33 
 
Table 1.Baseline characteristics of patients according to the type of STEMI 
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2. Prevalence of MR 
27(22.7%) patients were found to have MR during index admission for MI (Figure 
8), out of which 24(88.9%) had mild MR and 3(11.1%) had moderate MR based on 
quantitative measurements. None of the patients were found to have severe MR. 
Mean Vena contracta (VC) in mild and moderate MR patients at presentation were 
2.91±0.94 and 3.54±0.25 respectively. Mean PISA radius, effective regurgitant 
orifice area (ERO) and regurgitation volume in mild MR patients at presentation 
were 0.315±0.08, 0.05±0.03 and 7.07±3.65 respectively (table 2). 
MR VC(mm) PISA 
radius(cm) 
ERO(cm2) MR 
Volume(ml) 
MILD(n=24) 2.91±0.94 0.315±0.08 0.05±0.03 7.07±3.65 
MODERATE(n=3) 3.54±0.25 0.44±0.06 0.10±0.06 30.33±7.77 
AFTER 1 MONTH    
MILD(n=12) 2.97±0.55 0.38±0.81 0.05±0.03 6.9±3.17 
MODERATE(n=2) 4.8±8.5 0.55±0.07 0.125±0.02 27±1.41 
 
Table 2.Quantitative echocardiographic parameters of MR at presentation and after 
1 month 
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Mean age of patients presenting with ischaemic MR at onset was 59.2 ± 
10.82(figure 9), population includes 74.1% males (20) and 25.9 %( 7) females. 
Majority of patients presenting with MR at admission were in the age group of 60-
79 years (figure 9).Among the patients having MR at admission included 
48.1%(13) type 2 diabetics, 100%(27) dyslipidemics, 33.3 % (9) hypertensive’s, 
44.4% (12) obese, 44.4 %(12) current smoker, 22.2%(6) had AWMI, 77.8%(21) 
had IWMI and none had a positive family history of coronary artery disease 
(CAD). Though there was trend towards females being more commonly associated 
with MR, it was found to be statistically insignificant (figure 10). None of the risk 
factors predicted of onset of MR in STEMI patients at admission and during follow 
up on statistical analysis except age, diabetes and site of STEMI(Table 3).IWMI 
patients were more likely to develop MR at presentation (table 3).Male gender was 
found to have higher prevalence of absence of MR during follow up. 
 
 
 
 
 
 Figure 8.Prevalence of MR at admission
 
Figure 9.Prevalence of MR according to the age groups
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During follow up after 1 month, MR was found to be present in 15.7% of patients 
despite a dropout of 30(25.2
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developed new onset MR, but it was not statistically significant (p
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3).None of the patients with positive family history had Mitral Regurgitation at 
onset. Development of MR in STEMI patients was not influenced by the treatment 
modality used (figure 13). 
Figure 11.Prevalence of MR after 1 month
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(11.1%) patients had moderate MR, but
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 Figure 13.Prevalence of MR in relation to treatment strategies
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Site of STEMI 
AWMI(60) 
IWMI(59) 
 
6(22.2) 
21(77.8) 
 
0.001* 
 
  3(21.4) 
11(78.6) 
 
0.03* 
Diabetes(n=38) 13(48.1) 0.04*  5(35.7) 0.612 
Hypertension(n=45) 9(33.3) 0.585 4(28.6) 0.615 
Smoking(n=56) 12(44.4) 0.757 5(35.7) 0.210 
Dyslipidemia(n=117) 27((100) 0.44 14(100) 0.539 
Obesity(n=65) 12(44.4) 0.36 5(35.7) 0.257 
Positive Family 
History(n=16) 
0(0) 0.02* 1(7.1) 0.458 
Baseline 2D EF 48.17±8.93  
0.769 
 50.2±8.6  
0.216 Baseline 3D EF 46.24±7.68  50.37±8.61 
Reperfusion modality 
Thrombolysis (n=45) 
Primary PCI (n=62) 
Miscc(n=12) 
 
 
11(40.7) 
14(51.9) 
    2(7.4) 
 
 
0.744 
 
8(57.1) 
6(42.9) 
0(0) 
 
 
0.134 
Table 3.Comparison of various variables with MR at onset and during follow up 
*statistically significant 
 
46 
 MR   Sex Total p value 
    1(Male) 2(Female)   
Absent  Number of 
patients 
69 7 76 
 
     (88.5%) (58.3%) 84.4% 0.019* 
 
Present 
 Number of 
patients 
9 5 14 
 
     (11.5%) (41.7%) 15.6%  
Total Total no. 78 12 90  
  % within sex 100.0% 100.0% 100.0%  
 
Table 4. Association of sex with the prevalence of Mitral Regurgitation at 1 month 
Severity  Baseline 
MR  
MR at FU 
Mild 24(88.9) 12(85.7) 
Moderate 3(11.1) 2(14.2) 
Severe - - 
 
Figure 14.Prevalence of severity of MR at onset and after 1 month 
 Figure 15.Prevalence of MR in relation to type of MI
3. Correlation among 2D and 3D EF in STEMI
Mean 2D EF in AWMI group at presentation was 44.94
group was slightly higher 50.7
better in IWMI patients on presentation. After
2D EF by 6.9%(51.83±8.06)
group (51.05±8.4).2D EF was found to 
and during follow up irrespective of type of 
quality was one of the hindering factor
scatter plot displaying the distribution of 2D and 3D EF at baseline.
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2D and 3D EF Correlation 
coefficient, r 
 p (2 tailed) 
At admission 0.525 0.01 
At 1 month 0.609 0.01 
 
Table 5.Correlations of 2D and 3D EF at admission and after 1 month 
 
Figure 16.Scatter plot showing relationship of 2D-EF and 3D-EF at admission 
(Pearson correlation coefficient r, 0.525) 
* Correlation is significant at the 0.01 level (2-tailed). 
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DISCUSSION 
The present study is a prospective observational study which evaluated the 
prevalence of functional (ischaemic) mitral regurgitation in patients with STEMI at 
presentation and during 1 month of follow up. Mean age of patients was 53.42 ± 
11.47 years with majority of them being males (83%). Most common age group 
was found to be 40-59 years (57.1%), with least patients in >80 yrs (2.5%).10.9% 
patients had MI in young (<40 years).Our results are found to be similar as 
observed in a large retrospective analysis by Brijesh et al92 done in our institute. 
Most common risk factor was found to be dyslipidemia(98.3%) , followed by 
obesity(54.6%),smoking (47.1%),diabetes(31.9 %), hypertension (37.8%) and  
positive family history of coronary artery disease(13.4%). This data is different 
from create study where diabetics 34% had diabetes; 37.7% had hypertension; and 
40.2% were smoker.93 All patients were having multiple coronary risk factors.LV 
systolic function was found to be better in IWMI patients at presentation as lesser 
territory was compromised by ischaemia. Similar results were observed by Darbar 
et al and our findings are consistent with it.94 With anterior infarction, the injury is 
exclusively in the left ventricle, whereas inferior infarction is associated with 
injury to both ventricles, causing less impairment of left ventricular function 
despite an equivalent overall myocardial insult. After 1 month, there was a trend in 
the increase in 2D EF by 6.9% in AWMI group due to revascularisation therapy.95     
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MR was found in 22.7% at presentation of STEMI in our study population, which 
is in accordance with older studies including angiographic ones (table 5). It was 
found to be higher in older age group, diabetics and IWMI patients at the onset, 
which was consistent with previous studies.2, 12, 15 There was a trend toward an 
excess of women in the MR group, though it was not statistically significant due to 
under representation of females in present study. Similar data on the demographics 
of MR after AMI have been presented earlier by Lehmann, Tcheng, and Barzilai.2, 
12, 15
 IWMI involves the posterior wall of LV leading to left ventricle remodelling 
and distortion. This result in apico-lateral as well as posterior displacement of 
papillary muscle, which in turn leads to apical displacement of mitral leaflet 
coaptation point, producing the ischaemic mitral regurgitation.8 Mostly patients 
had mild MR and none had severe MR which is possibly due to exclusion of very 
sick patients like cardiogenic shock. During follow up after 1 month, MR was 
found to be in 15.7% of patients despite a dropout of 30(25.2%) patients. Some 
patients with MR tend to improve with the resolution of acute ischaemia due to 
revascularisation as well as favourable LV remodelling and improvement in LV 
systolic function, while some had deteriorated with worsening mitral regurgitation 
due to adverse left ventricular remodelling with passage of time after STEMI. 
Treatment modality used didn’t influence the development of MR as shown earlier 
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by Tcheng JE et al. Acute reperfusion with thrombolysis or angioplasty did not 
reliably reverse valvular incompetence as seen in earlier observational studies. 
None of the baseline risk factor except diabetes, territory involved and older age 
group ,can reliably predict the development of MR at onset and left ventricle 
systolic function, though this study was not powered enough to study those 
predictors. IWMI patients tend to have higher prevalence of MR during the STEMI 
as well as during follow up secondary to tethering effect on the mitral valve leaflet 
which may be a harbinger of chronic MR later on. Treatment modality didn’t 
influence the severity of MR in STEMI patients.  
Author Year No of 
patients 
Modality used Prevalence 
of MR (%) 
Barzilai B et al15 1988 1480 Echo 39 
Tcheng JE et al12 1992 1480 Echo 17.9 
Lehmann KG et al2 1992 206 LV 
ventriculography 
13 
Gervasio A. Lamas 
et al3 
1997 727 LV 
ventriculography 
19.4 
Present study 2013 119 Echo 22.7 
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2D EF was found to correlate linearly with 3D EF irrespective of type of STEMI. 
In a recently published metanalysis, Jennifer L. Dorosz et al96 showed similar 
results. With EF, there is no difference in the bias between 3DE and 2DE, and the 
difference in the variance is modest (± 4.7%). Despite being subjected to errors due 
to foreshortening, poor endocardial definition, narrow echocardiographic windows, 
and assumptions about LV shape, it remains a ubiquitous tool for assessing LV 
size and systolic function in day to day clinical practise. 
 Although 3DE shows promise in providing the accessibility of echocardiography 
and the multi- planar imaging of CMR, this nascent technology still has limited 
spatial and temporal resolution compared with gold standard modality of CMR. 
Despite its limitations, 3DE may be superior to 2D techniques.  
Our single centre study shades light on the prevalence of Mitral Regurgitation in 
acute STEMI in Indian population. MI is most prevalent in middle age persons 
with ischaemic Mitral Regurgitation in slightly older age group. Modalities of 
revascularisation (mechanical vs thrombolytic or medical treatment doesn’t 
influence the course of Mitral Regurgitation in short term follow up. However, 
these findings need to be confirmed in larger study population MI. 
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STUDY LIMITATIONS 
 The main limitation of this study was smaller sample size, which was not powered 
enough to study the predictors of development of MR in STEMI patients. 
Moreover, females were underrepresented in the study group, which may have 
negated the gender effect on ischemic MR. Critically ill patients , cardiogenic 
shock etc  were not included in whom ,there is a probability of having severe 
mechanical complications of STEMI like severe MR. There was a significant drop 
out during follow up, which may have influenced the statistical analysis. 
Only echocardiographic LV systolic function measurements were used and were 
not compared with other imaging modalities like MRI, which is gold standard for 
determining EF in patients with regional wall motion abnormalities. Longer follow 
up periods are required for assessing the development of chronic ischaemic MR. 
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 CONCLUSION 
STEMI patients have 22.7% prevalence of MR at onset, which is more likely in 
older age group, diabetics and IWMI patients and independent of gender and left 
ventricle systolic dysfunction. Despite under-representation of females in our study 
population, they seem to carry higher risk of development of ischaemic Mitral 
Regurgitation in India. Most commonly, ischaemic MR is of milder severity at 
onset which tends to persist in 15.7% of patients during follow up. There is a 
significant association of development of ischaemic MR during acute STEMI with 
IWMI. Some patients may develop new MR later on depending on the LV 
remodelling. 2D EF estimation with a properly acquired good image is comparable 
to more precise 3D EF in STEMI patients.  
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INFORMATION SHEET 
Prevalence and Echocardiographic assessment of Mitral Regurgitation 
including 3D-EF [Ejection fraction] assessment in Acute ST Elevation 
Myocardial Infarction 
1. This study is for research purpose and to study the prevalence and 
echocardiographic assessment of Mitral Regurgitation including 3D-EF 
[Ejection fraction] assessment in Acute ST Elevation Myocardial Infarction 
2. Expected duration : 1 year 
3. Description of the procedures – ECG and ECHO  
4. No foreseeable risks or discomforts to the subject 
5. No direct benefit to the subject 
6. No alternative procedures available to the subject 
7. Complete confidentiality of records identifying the subject will be 
maintained by Principal Investigator. 
8. No compensation available to the subject in the event of a study – related 
injury 
9. No anticipated prorated payment to the subject 
10. No subjects responsibilities on participation 
11. Subject’s participation is voluntary, that the subject can withdraw from the 
study at any time and that refusal to participate will not involve any penalty 
or loss of benefits to which the subject is otherwise entitled 
12. No apparent foreseeable circumstances under which the subject’s 
participation may be terminated by the investigator without the subject’s 
content. 
13. No additional costs to the subject that may result from participation in the 
study 
14. Subject can withdraw from the research and procedures at any time of study 
15. There will be no consequences on subjects decision to withdraw from the 
research 
16. Subject or subject’s representative will be notified in a timely manner if 
significant new findings develop during the course of the research which 
may be affect the subject’s willingness to continue participation will be 
provided 
17. We are not involving pregnant women in our study 
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18. Approximate number of subjects enrolled in the study – 100 patients 
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                               STUDY PROFORMA 
 
                         DATA ABSTRACTION FORM 
 
 
 
DATE OF ENROLMENT:                                            ENROLMENT NO. : 
 
NAME:                                   AGE:                               HOSPITAL NO.: 
 
ADDRESS: 
 
 
PHONE: 
 
 
CLINICAL DIAGNOSIS:                                             BMI: 
 
 
 
HR:                      
 
BP:                                                       
                                                   
 
 
CLINICAL 
CHARACTERISTICS 
 
AGE  
SEX  
DM  
SMOKING  
HTN  
ALCHOLISM  
DYSLIPIDEMIA  
OBESITY  
FAMILY HISTORY OF CAD  
REPERFUSION  
MI  
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Age Group  
20-39yrs 1 
40-59yrs 2 
60-79yrs 3 
≥80yrs  4 
SEX-1[MALE], 2[FEMALE] 
RISK FACTOR-1(PRESENT)/2(ABSENT) 
MI-1(AWMI)/2(IWMI) 
REPERFUSION: 1 (THROMBOLYSIS)/2(PCI)/3(Miscellaneous) 
 
 
 
 
MR SEVERITY: 
 
 
 
DURING 
HOSPITALISATION 
AFTER 1 MONTH 
JET AREA 
1. PLAX 
2. A4C 
 
  
VENA CONTRACTA 
(mm) 
  
PISA 
a. PISA radius(cm) 
b. EROA(cm2) 
c. Regurgitant volume(R 
vol) 
 
  
MR SEVERITY   
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MR SEVERITY- 0[Absent], 1[Mild], 2[Moderate], 3[Severe] 
 
 
 
 
LEFT VENTRICULAR SYSTOLIC FUNCTION PARAMETERS 
 
 
 DURING 
HOSPITALISATION 
AFTER 1 MONTH 
LVIDd (cm)   
LVIDs (cm)   
2D-EDV   
2D-ESV   
2D-EF   
3D-EDV   
3D-ESV   
3D-EF   
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                            GLOSSARY FOR MASTER CHART 
H.NO: Hospital number 
AGE (in years)  
1= 20-39yrs  
2= 40-59yrs  
3= 60-79yrs  
4= ≥80yrs   
SEX: 1=MALE], 2=FEMALE 
RISK FACTOR: 1=PRESENT, 2=ABSENT 
STEMI: Site of STEMI 
1= AWMI 
2= IWMI 
DM: Diabetes Mellitus 
HTN: Hypertension 
SM: Smoker 
DL: Dyslipidemia 
FH: Family history of CAD 
SITE OF MYOCARDIAL INFARCTION (MI): 1=AWMI, 2=IWMI 
REP: REPERFUSION 
 1=THROMBOLYSIS), 2=PCI, 3=Miscellaneous 
EF: Ejection fraction 
LVF: LEFT VENTRICULAR SYSTOLIC (LV) FUNCTION ( %)    
Normal: 1= ≥55% 
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Mild Dysfunction : 2= 45-54% 
Moderate Dysfunction:  3= 30-44% 
Severe Dysfunction:  4= <30%   
BODY MASS INDEX (BMI)  
Overweight: 1= 24.9   
Normal: 2= 18.4-24.9   
Underweight: 3= <18.4  
MITRAL REGURGITATION (MR)   
0= Absent  
1= Mild   
2= Moderate 
3= Severe 
MRJA: MR jet area 
LAA: Left atrium area 
PLAX: Parasternal long axis view 
A4C: Apical 4 chamber view 
VC: Vena contracta 
RAD: Proximal isovelocity surface area radius 
EROA: Effective regurgitant orifice area 
PISA: Proximal isovelocity surface area 
R Vol: Regurgitant volume 
LVIDd: Left ventricular internal diameter in diastole 
LVIDs: Left ventricular internal diameter in systole 
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2D EDV: 2D end-diastolic volume 
2D ESV: 2D end-systolic volume 
3D EDV: 3D end-diastolic volume 
3D ESV: 3D end-systolic volume 
2D EF: 2D ejection fraction 
3D EF: 3D ejection fraction 
MR STATUS 
1= Improvement 
2= Persistent 
3= Deterioration 
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PROFORMA FOR PATIENT’S DATA COLLECTION 
 
“ATRIAL FIBRILLATION AND THROMBOEMBOLIC RISK- 
DEMOGRAPHIC, CLINICAL AND ECHOCARDIOGRAPHIC  
 (TRANSTHORACIC VS. TRANSOESOPHAGEAL) 
EVALUATION”  
 
 
Name                                       Age         Sex                            Address 
 
Symptoms  
 Dyspnoea               Class                   Duration 
Orthopnoea 
PND 
Palpitation               Class                   Duration 
Odema legs 
Thromboembolic phenomena  
      Stroke 
      TIA 
      Peripheral embolism 
Chest pain 
Haemoptysis 
Others 
Cardiac failure/LV dysfunction 
Hypertension    diabetes       age ≥75 y ;65-74 y; <65 years  
Vascular disease-PAD/MI 
Signs      
Pulse                           BP                            JVP                                            
Apex 
S1  
A2 P2  
OS  
MDM/PSM/ESM 
 
ECG 
CXR                         PA VIEW                                              LATERAL 
VIEW 
 
TRANSTHORACIC ECHOCARDIOGRAM 
Chamber dimensions & function 
LV RV 
LVEF by M MODE(PLAX/PSAX) 
RA volume – A4C 
LA volume –A4C, A2C (volume assessed by modified simpson’s 
method) 
 
MR                 TR                        PAP 
 
Other valves 
Thrombus           Site                    Size  
 
LA 
LAA 
LA –SEC 
 
 
TRANSOESOPHAGEAL ECHOCARDIOGRAPHY 
 
LA-SEC 
LAA Thrombus Present /Absent 
Site 
Size 
Mobility 
LA Appendage peak emptying velocity cm /sec 
 
Any other interesting finding 
 
 
Medical treatment 
 
Digoxin    Lasix    Aldactone   Penicillin    KCL 
Verapamil        Others 
 
Oral Anticoagulation-Acitrom(Acenocomorol) mgs OD daily 
 
Scoring for non valvular heart disease 
 
CHADS2 score 
 
CHA2DS2-VaSc score 
 
H.No. Age Sex STEMI DM HTN SM DL BMI FH REP MRJA(PLAX) MRJA(A4C) VC Rad ERO R Vol(ml) MR  LVIDd LVIDs 2D EDV 2D ESV 2D EF LV F 3D EDV 3D ESV 3D EF
1 054103F 47 2 2 1 1 2 1 1 2 2 0 3.8 2.5 43 22 51.2 2 58.6 25.6 56.4
2 238274C 60 1 1 1 1 1 1 2 2 1 0 3.9 2.9 65.9 30.9 53.2 3 63.5 30.4 52.1
3 057118F 55 2 1 2 1 2 1 1 1 3 0 5.4 4.6 109 68 37.6 3 98 56.2 42.6
4 064339F 48 1 1 2 2 1 1 2 2 1 2.4/11.6 2/8.3 2.5 0.2 0.02 2 1 4.9 3.9 113.5 67.4 40.6 3 62.2 29 53.4
5 065890F 72 1 2 2 2 1 1 1 2 1 0 5 4 118.2 70 40.8 3 73.3 42.3 42.3
6 055388F 50 1 2 2 1 1 1 1 2 1 0 4.1 3.1 59 28 52.5 2 58.1 24.6 57.7
7 054675F 55 1 2 2 2 2 1 1 2 1 1.78/10.4 2/14.8 2.6 0.3 0.03 5 1 4.7 3.6 101.5 54.5 46.3 2 97.5 55.2 43.4
8 054634F 43 1 1 2 2 1 1 2 1 2 0 5 3.9 82.5 51.6 37.5 3 76.3 49.9 34.6
9 054488F 49 2 2 2 1 2 1 1 1 2 0 3.7 2.5 56.2 25.3 55 1 74.6 41.3 44.6
10 054408F 41 1 2 2 2 2 1 1 2 2 1.8/15.8 2.1/15.4 2.4 0.3 0.04 6 1 4.9 3.5 70 66 51.5 2 84.5 43.4 48.6
11 054547F 35 1 1 1 2 1 1 2 2 1 0 4.7 3.8 93 51 45.2 2 88.9 47.8 46.2
12 050273F 68 1 1 1 2 2 1 1 2 3 0 4.7 3.6 85 32 62.4 1 80.7 33.2 58.7
13 057169F 37 1 2 2 2 2 1 2 1 3 0 4.2 2.9 76.8 35.3 54 2 84.2 41.4 50.8
14 077453A 48 1 1 1 1 1 1 1 2 2 0 3.6 2.6 54.4 24.6 54.8 2 50.5 22.4 55.6
15 069862F 65 2 2 1 2 2 1 2 2 1 3.7/14.7 4.5/16.5 5.2 0.4 0.07 9 1 4.7 3.6 102.4 54.4 46.8 2 75.2 34 54.7
16 882378D 73 1 2 1 1 2 1 1 2 2 5.8/17.6 6.3/18 4.4 0.6 0.14 24 2 4 3.3 70.4 43.1 38.8 3 69.1 38.9 43.7
17 073346F 50 1 2 2 2 2 1 1 2 1 4.4/13.2 1.6/8.68 2.9 0.4 0.11 15 1 4 2.8 67.9 29.6 56.5 1 59 27.7 53.5
18 077605F 61 1 1 1 2 2 1 1 1 2 0 4.1 2.8 74.2 28.7 61.3 1 63 32.4 48.5
19 077583F 60 2 1 2 1 2 1 2 2 1 0 3.7 2.8 58.1 29.6 49.2 2 57.4 37.9 34
20 225068D 68 1 1 2 1 2 1 1 2 2 0 4.4 3.2 87.7 41.7 52.4 2 69.1 38.9 43.7
21 077403F 49 1 1 2 1 2 1 1 2 2 0 5.1 4 123.8 72.1 41.8 3 74.4 29.9 59.8
22 107333F 49 2 1 2 2 2 1 1 2 2 0 3 2.5 35 22.3 36.2 3 67.9 39.5 41.8
23 107374F 45 1 2 2 1 2 1 1 2 1 0 3.7 2.6 58.1 24.6 57.7 1 39.7 27.8 29
24 107254F 29 1 1 2 2 1 1 2 1 1 0 4.3 3.2 85.4 39.4 53.8 2 70 34.6 50.6
25 107146F 50 2 2 2 2 2 1 1 2 1 0 3.9 2.4 65.9 20.2 69.4 1 82.2 28.3 65.6
26 107169F 55 1 1 2 2 1 1 1 1 1 0 5.2 3.6 129.5 54.4 58 1 62.3 31.2 50
27 102418F 38 1 2 2 2 2 1 1 2 2 0 4.2 3.3 78.6 44.1 43.8 3 84.3 44.8 46.8
28 107046F 32 1 1 2 2 1 1 1 2 1 0 5 3.8 118.2 62 47.6 2 103.6 48 53
29 188849C 56 1 1 2 1 1 1 1 1 2 0 5 4.1 121 76.4 36.9 3 72.9 39.9 45.3
30 107022F 68 1 2 2 1 2 1 1 2 2 1.7/11 1.2/9.5 3.6 0.4 0.07 10 1 4.4 3.5 87.7 50.9 42 3 164 76.6 53.6
31 102288F 42 1 1 1 1 1 1 2 2 2 0 4.1 3.2 76.4 41 46.4 2 56.8 28.7 49.5
32 102275F 59 1 2 2 2 1 1 1 2 2 0 4.8 3.5 107.5 50.9 52.7 2 46.6 27.9 52.2
Master Chart ‐ Baseline characteristics at index hospitalization 
33 102272F 45 1 1 2 2 1 1 2 2 1 0 4.2 3.1 78.6 37.9 51.7 2 69.7 28.7 58.8
34 102281F 45 1 2 1 1 2 1 2 2 1 0 4.7 3.3 38 17 55.3 1 40.5 28.8 28.8
35 119004F 30 1 1 1 2 1 1 1 2 2 0 4.1 3.2 56.8 34 40 3 50.2 27.6 45
36 112993F 52 2 1 1 1 2 1 1 2 2 0 3.5 2.5 51.6 21.4 58.4 1 64 28 56.2
37 112996F 61 1 2 2 2 2 1 2 2 1 0 4 3.1 67.9 39.4 42 3 75.6 50.8 32.8
38 729726C 36 1 2 2 2 1 1 1 2 2 0 4.5 3.5 94.4 51.4 45.5 2 98.6 60.5 38.6
39 054139F 60 1 1 1 2 2 1 1 2 2 0 4.6 3.8 97.3 62 36.4 3 88 50.68 42.4
40 112859F 52 1 1 1 1 2 1 2 2 2 0 5.7 4.7 160 102.4 36 3 61.9 40.4 34.8
41 118041F 59 1 2 2 2 1 1 1 2 1 3.7/10.9 4/11.7 3.1 0.4 0.06 10 1 6.1 4.3 186.2 85.4 54.2 2 78.9 43.4 45
42 112856F 31 1 2 2 2 1 1 2 2 2 3.6/18 5/17.6 5.2 0.3 0.04 6 1 5.6 4.1 153.7 74.2 51.7 2 103.1 53.4 48.1
43 115998F 43 1 1 2 2 2 1 1 1 2 0 3.4 2.7 47.4 27 43 3 56.8 31.7 44.2
44 110143F 49 1 1 1 1 2 1 1 2 2 0 4 3.1 70 37.9 45.8 2 66.2 26.2 60.5
45 112533F 61 1 2 1 1 2 1 2 2 3 1.7/12.4 1.8/9.5 2.3 0.3 0.03 6 1 4.1 3.2 74.2 41 44.8 2 84 48.6 42.2
46 112611F 66 1 1 2 2 2 1 1 2 1 0 4.3 3.3 54.6 31.7 42 3 58.7 30.8 40.7
47 112508F 39 2 1 2 2 2 1 1 2 3 0 4.4 3.5 89.3 50.9 43 3 39.5 14.2 64
48 102124F 39 1 1 2 2 2 1 2 1 3 0 5.1 4 123.8 70 43.5 3 45.9 31.3 31.8
49 101269F 55 1 2 2 2 1 1 2 2 1 0 3.9 2.7 65.9 27 59 1 51.7 17.8 65.6
50 098767F 51 1 1 2 2 1 1 1 2 2 0 4.2 3.2 78.6 41 47.9 2 72.4 39.7 45.1
51 098764F 50 1 2 2 2 2 1 2 2 2 0 4.5 3.2 90.1 41 54.5 2 72.6 32 55.9
52 098685F 55 1 1 2 2 1 1 2 2 1 0 4.9 4 112.8 70 38 3 78.3 49.2 37.1
53 090246F 45 1 2 2 2 2 1 1 2 3 0 4.2 3.3 78.6 44.1 43.8 3 57.5 30.6 46.8
54 927328D 57 1 1 1 2 2 1 1 1 3 0 4.9 4.1 112.8 74.2 34.2 3 56.7 35.5 37.3
55 662271C 38 1 2 2 2 2 1 2 1 2 0 5.1 4 123.8 70 43.5 3 56.8 31.7 44.2
56 094969F 59 1 2 1 2 2 1 2 2 1 2.6/12.8 3.4/13.6 1.5 0.3 0.04 5 1 4 2.9 70 32.2 54 1 37.1 13.9 62.5
57 098619F 50 2 2 1 1 2 1 2 2 1 3.1/10.6 6.8/12.3 4.6 0.6 0.16 28 2 3.5 2.7 50.9 27 46.9 2 53.7 34.1 36.4
58 098590F 43 1 2 2 2 2 1 1 2 1 0 4.5 3.4 92.4 47.4 48.7 2 75.2 37.3 50.5
59 098521F 52 1 2 1 2 1 1 2 2 2 2.1/13.9 2.6/14.2 2.5 0.4 0.07 4 1 6 4.5 180 90.1 50 2 87.6 56.4 35.6
60 094810F 65 1 1 1 1 1 1 2 2 2 2.3/8.4 1.6/6 2.5 0.2 0.02 2 1 5 4 118.2 70 40.8 3 82.4 57.4 30.3
61 578325C 55 1 2 1 2 1 1 2 2 2 1.7/8 1.4/7.2 3.1 0.4 0.07 8 1 4.9 3.6 112.8 54.4 51.8 2 100.8 46.4 54
62 097655F 60 1 1 1 2 1 1 2 2 2 2.2/12.6 2.5/11.4 2.5 0.3 0.04 4 1 5.4 4.6 141.3 95.7 32.3 3 107.9 71.1 39.1
63 094712F 55 1 2 2 2 2 1 2 2 2 0 4.8 3.3 107.5 44.1 59 1 98.8 43.1 56.4
64 094702F 65 1 2 1 2 1 1 2 2 2 1.9/11.8 2.2/11.3 2.7 0.3 0.04 6 1 4.9 3.8 110.2 62 43.8 3 109.5 58.8 46.3
65 094553F 36 1 2 2 2 1 1 1 1 1 0 4 2.6 67.9 24.6 63.8 1 94.7 44.3 53.2
66 094459F 44 1 2 2 2 1 1 1 2 2 1.8/15.7 1.4/8.6 2.6 0.2 0.02 3 1 4.8 3.2 107.5 41 61.9 1 73.9 37.5 49.3
67 093552F 65 1 2 1 1 1 1 1 2 2 1.3/11 1.2/12 3.5 0.2 0.02 3 1 3.9 2.7 63.9 27.8 56.4 1 56.8 27.1 52.3
68 092687F 60 2 1 2 1 2 1 2 2 1 0 4.5 3.5 92.4 50.9 45 2 64.8 27.1 58.2
69 089713F 65 2 1 2 1 2 1 1 2 1 0 4.3 3.3 80.8 44.1 45.4 2 71.3 42.6 40.2
70 089728F 58 2 2 1 2 1 1 1 2 3 0 4.1 3.1 74.2 37.9 48.9 2 49.7 26.9 45.9
71 089921F 53 2 2 2 2 2 1 1 2 2 2.3/9.1 2.7/8.9 1.9 0.5 0.1 14 1 3.7 2.3 58.1 18.1 68.8 1 50.3 26.7 46.9
72 685616C 51 1 1 2 1 2 1 1 2 1 0 4.9 3.9 112.8 65.9 41.6 3 102.4 57.9 43.4
73 089991F 70 2 2 2 2 2 1 3 2 1 5.3/17.4 5.1/13/ 2.6 0.4 0.07 11 1 3.9 2.6 65.9 24.6 62.7 1 78.4 32.8 58.2
74 089887F 65 2 1 2 2 2 1 1 2 1 0 4.1 3.2 68.4 41 40 3 76.4 46.8 38.8
75 088032F 40 1 2 2 2 1 1 2 2 2 0 4.2 3.1 78.6 38.9 50.5 2 75.2 33.1 56
76 089857F 50 2 1 2 1 2 1 1 2 3 0 4.6 3.5 88.2 52.2 40.8 3 97.4 56.4 42.1
77 089599f 78 1 1 2 1 1 2 2 2 2 0 5.5 4.4 146.8 87.7 40.3 3 136.2 82.3 39.6
78 089863F 61 1 2 2 1 1 1 1 2 1 0 4.5 3.4 90.1 49.1 45.4 2 97.3 50 48.6
79 088472F 45 2 1 1 2 2 1 2 2 2 0 2.9 2.3 32.2 18.1 43.7 2 56.7 30.6 46.1
80 089412F 53 1 1 2 1 1 1 2 2 2 0 4.8 3.5 76.2 39.6 48 2 56.9 29.5 48.1
81 089405F 56 1 1 2 2 1 1 2 2 2 0 5.1 4 123.8 70 43.5 3 86.6 46.2 46.7
82 084441F 40 1 2 2 2 1 1 2 2 2 0 5 3.5 118.2 50.9 57 1 82.2 45.1 45.1
83 300574C 59 1 2 1 2 2 1 2 2 2 0 4.4 3 86.1 36.3 57.8 1 88.6 50.1 43.5
84 085060F 43 1 1 2 2 1 1 1 2 1 0 4.1 3.2 74.2 41 44.8 2 114.9 60.1 47.7
85 077488F 67 1 2 1 1 1 1 2 2 2 0 4.9 3.8 112.8 63.9 43.3 3 103.1 74.1 28.1
86 077667F 70 2 1 1 1 2 1 1 2 1 4.3/17.4 5/18.2 3.3 0.4 0.06 9 1 4.2 3.4 78.6 47.4 39.6 3 88.2 44.7 49.3
87 077610F 82 1 1 2 1 2 1 2 2 1 2.4/15.3 2.7/13.8 2.3 0.4 0.07 12 1 5 4.1 121 74.2 38.7 3 61.3 37.8 38.3
88 368074A 77 1 2 2 1 2 1 1 1 2 0 3.6 2.9 54.4 32.2 40.8 3 67.4 38.9 42.3
89 054634F 43 1 1 2 2 1 1 1 2 2 0 4.5 3.6 92.4 54.4 41.1 3 98.3 61.1 37.8
90 080409F 60 1 1 1 2 2 1 1 2 1 0 4.5 3.5 94.9 50.9 46.4 2 53 32.6 38.1
91 328853F 35 1 1 2 2 1 1 2 1 1 0 4.6 3.8 99.8 62 37.9 3 89.7 52.5 41.5
92 331075F 65 1 2 2 2 1 1 2 2 1 1.21/15 1.99/13 2.9 0.2 0.06 8 1 4.5 3.1 92.4 37.9 59 1 90.3 49.2 45.5
93 322267F 47 1 1 2 2 1 1 2 2 1 0 4.1 3.2 74.2 41 44.8 2 47 32.2 31.6
94 495506C 64 1 2 1 2 1 1 1 2 2 1.4/11.9 3.3/17.5 4.9 0.5 0.04 39 2 4.9 3.9 112.8 65.9 41.6 3 110.8 67.6 39
95 322632F 58 1 2 1 1 1 1 1 1 2 0 5.2 4.1 129.5 73.5 43.2 3 132.5 77.8 41.3
96 327344F 80 2 2 1 1 2 1 1 2 2 0 4 3.2 70.1 41.5 40.8 3 64.2 45.5 29.1
97 327352F 65 2 2 2 2 2 1 2 2 2 0.9/14 3.95/16.6 3.1 0.3 0.12 10 1 4.6 3.7 97.8 58.1 40.6 3 67.4 33.2 43
98 322650F 45 1 2 2 2 1 1 2 2 2 0 4.2 3.1 80.1 36.6 54.3 2 62.3 31.8 49
99 322636F 47 1 1 1 1 2 1 1 2 2 0 3.9 2.8 67.9 28.3 58.4 1 72 40.1 44.3
100 433108D 40 1 1 2 2 1 1 1 2 1 0 5 4 121 72.1 40.4 3 76.5 46.8 38.8
101 347512F 63 2 1 2 1 2 1 1 2 3 2.61/14.5(PL 4.9 0.3 0.04 5 1 4.7 3.8 100.7 62 38.5 3 116.1 74 36.3
102 327307F 41 1 2 2 2 1 1 2 2 2 0 5.6 3.9 153.7 65.9 57.1 1 86.8 51.5 40.6
103 288407F 48 1 1 2 2 2 1 2 2 2 0 4.2 3.2 78.4 41.4 47.2 2 84 46 45.2
104 287354F 52 1 2 1 1 2 2 1 2 2 0 3.9 1.2 129.5 65.9 49.1 2 40 20 50
105 291306F 65 1 1 2 2 1 1 2 2 2 0 3.8 2.9 62 32.2 48 2 66.8 35.8 46.5
106 256769D 60 2 1 1 1 2 1 1 2 2 0 4 3.2 70 41 41.5 3 100 57.5 42.5
107 286849F 46 1 1 2 1 1 1 2 2 2 0 5 4.2 118.5 78.6 33.7 3 86 56.3 34.5
108 299314F 56 1 2 2 1 2 1 2 2 2 0 4.5 3.2 92.4 40.3 56.4 1 88.7 37.3 58
109 299336F 82 1 2 2 2 2 1 1 2 2 0 4.9 3.6 112.3 55.5 50.5 2 114.6 59.13 48.4
110 309758F 45 1 1 2 1 2 1 2 2 2 0 3.8 3 62 35 43.5 2 56 33 41.1
111 761606D 62 1 2 1 1 1 1 2 2 2 0 4.3 3.2 85.4 41 52 2 73 35.6 51.3
112 981786A 47 1 2 2 2 2 1 2 2 2 0 4.8 3.7 107.5 58.1 45.9 2 118 65 44.9
113 316403F 48 1 2 2 2 1 1 3 2 2 0 5.2 4.1 128.7 76.3 40.7 3 75 44 41.3
114 316458F 50 1 1 2 1 1 1 1 2 2 0 3.8 2.8 62.4 29.6 52.6 2 44 18 59.1
115 040901F 45 1 1 2 2 1 1 1 2 3 0 4.7 3.1 103.9 39.1 62.3 1 85.9 30.92 64
116 077397F 56 1 2 2 2 1 1 1 2 1 0 4.3 3.1 85 45 47.1 2 76 40.6 46.6
117 089817F 70 1 2 2 2 1 1 2 2 2 0 4.7 3.7 39 23 41 3 54.6 34 37.8
118 354481F 50 1 1 2 1 1 1 1 2 1 0 5.3 3.7 88 36 59.1 1 60.7 25.2 58.2
119 354493F 55 1 1 2 2 2 1 1 2 1 0 3.7 3 74 43 41.9 3 70.1 41.9 40.3
H.No. MRJA(PLAX) MRJA(A4C) VC Rad ERO R Vol(ml) MR  LVIDd LVIDs 2D EDV 2D ESV 2D LV F 3D EDV 3D ESV 3D EF
1 054103F 0 3.6 2.6 54.4 24.6 54.8 2 50.5 22.4 55.6
2 238274C 0 4.5 3.2 90.1 41 54.5 2 66.2 26.2 60.5
3 064339F 0 4.9 3.5 70 66 51.5 2 76.4 33.1 56.7
4 065890F 0 5.3 4.2 180 113 37.2 3 104.3 68.6 34.2
5 055388F 0 3.9 2.7 63.9 27.8 56.4 1 80.5 27.5 65.9
6 054675F 0 5 3.8 118.2 62 47.6 2 46.6 27.9 52.2
7 054634F 0 3.8 2.9 66 32 51.6 2 81 38.8 52.1
8 054408F 0 3.7 2.8 58.1 29.6 49.2 2 88.9 47.8 46.2
9 077453A 0 3.7 2.6 58.1 24.6 57.7 1 58.6 25.6 56.4
10 069862F 1.8/11 1.6/15 3.1 0.4 0.06 10 1 4.7 3.5 80 38 52.5 2 61.1 20.2 67
11 882378D 0 3.7 2.8 58.1 29.6 49.2 3 87.4 45.7 48
12 073346F 0 3.5 2.4 68 26 61.8 1 59 26.3 55.5
13 077605F 0 4.3 2.9 65 24 63.1 1 71.2 35.4 50.3
14 225068D 0 3.7 2.6 60.4 26.6 56 1 78.7 32.8 58.4
15 107254F 1.8/11 1.9/10.7(A4C 2.6 0.4 0.07 13 1 4.5 3.1 81 43 59 1 86.3 42.5 50.8
16 107146F 4.3/15.4 5.45/16(A4C) 3.5 0.3 0.04 7 1 4.1 2.9 120 43 56.6 1 113.6 63 44
17 107169F 0 5.2 3.6 129.5 54.4 58 1 64 28 56.2
18 102418F 0 4.7 3.8 75 42 44 3 75.7 38.6 49.1
19 107046F 0 4.8 3.5 107.5 50.9 52.7 2 74.4 29.9 59.8
20 188849C 0 6.4 5.1 124 81 34.7 3 91.4 52 43.2
21 107022F 2.4/8.4 2.8/7.44(A4C 3.4 0.3 0.04 5 1 5.6 3.4 79 24.5 69.1 1 56.2 28.9 48.6
22 102288F 0 5 3.8 62 28 54.8 2 62 29.2 52.9
23 102275F 0 4.7 3.3 38 17 55.3 2 72.6 32 55.9
24 102272F 0 4.9 3.3 63 26 58.7 1 102.1 45.8 55.2
25 102281F 0 5.4 3.7 76 39 48.7 2 63.8 39 38.8
26 119004F 0 4.5 3.6 111 66 40.5 3 88.9 52 41.5
27 112996F 1.4/13.8 1.2/14.2(A4C 2.3 0.3 0.04 5 1 4.9 3.8 97 55.3 43 3 63.6 36.9 42
28 118041F 2.5/11.6 3.8/12.8(A4C 2.1 0.2 0.01 2 1 5.6 4.2 158 91.64 42 3 113.4 58.97 40.8
29 112856F 6.7/22 7.7/22.5(A4C 5.1 0.5 0.1 10 1 5.6 4.8 163 110.84 32 3 146.6 106.2 27.6
30 115998F 0 5.2 4.2 105 63.74 39.3 3 93.1 55.3 40.6
31 110143F 0 4.8 3.2 146 65.7 55 1 58.7 27 54
32 112533F 0 4.5 3.2 90.1 41 54.5 2 78.4 32.8 58.2
Follow‐up data after 1 month
33 112611F 0 4.7 3.5 74 26 64.9 1 148.9 76.3 48.7
34 098767F 0 4.2 2.6 70 28 60 1 75.4 38 49.6
35 098764F 0 4.6 3.4 131 61 53.4 2 55.9 32.4 42.1
36 098685F 0 4.5 3.4 68 30 55.9 1 105.6 43.6 58.7
37 090246F 0 4.2 3.3 78.6 44.1 43.8 3 57.5 30.6 46.8
38 927328D 0 4.9 4.1 98.6 64.9 34.2 3 66.7 43.4 35
39 662271C 0 4.4 2.6 79 45 43 3 78.6 42.9 45.4
40 094969F 2.3/8.6 2.2/11.4 2.5 0.4 0.07 4 1 4.3 3.3 80.8 44.1 45.4 2 71.3 42.6 40.2
41 098590F 0 3.5 2.7 50.9 27 46.9 2 53.7 29.6 44.8
42 098521F 0 5.2 4.1 120 63 47.5 2 90 58 35.6
43 578325C 3.9/15.2 4.53/16.2 4.2 0.5 0.11 26 2 4.9 3.5 93 52 44 3 84.7 52.4 38.1
44 094712F 0 5.5 3.4 120 68 43.3 3 58.5 31.8 45.6
45 094702F 0 5.3 4 98 48 51 2 131.6 100 24
46 094553F 0 4.2 2.8 88 38 56.8 1 80.9 32.5 59.8
47 094459F 0 4.4 3 86.1 36.3 57.8 1 69 28.4 58.8
48 093552F 0 4.8 3.2 107.5 41 61.9 1 74.2 28.7 61.3
49 089728F 0 4.7 3.4 89 22 75.3 1 71 38.7 45.4
50 089921F 0 4.1 2.5 90 34 62.2 1 56.7 20.4 64
51 685616C 0 4.1 2.7 59 31 47.5 2 67.4 35 48
52 089887F 0 4.1 3.2 68.4 40 40 3 80 48.9 38.8
53 088032F 0 4.7 3.4 81 36 55.6 1 69.1 34.7 49.8
54 089857F 0 5.3 4 86 38 55.8 1 82.7 38 54.1
55 089599f 0 5.2 3.5 129.5 52 59.8 1 66.6 38.2 42.6
56 088472F 0 3.5 2.5 89 39 56.2 1 57.9 23.7 59.1
57 089412F 0 5.3 4 66 23 65.2 1 69 28.4 58.8
58 089405F 0 4.5 2.9 116 35.1 46 2 65.4 35.2 46.2
59 300574C 0 4.4 3.2 65 36 44.6 3 62.8 35.7 43.1
60 077488F 0 5.5 4.5 93 58.04 37.6 3 95.5 63.3 33.7
61 077667F 3.09/9.68 4.23/15.7 2.4 0.3 0.03 6 1 5.5 4.4 146.8 87.7 40.3 3 61.3 37.8 38.3
62 368074A 0 4.1 2.7 67 31 53.7 2 60.9 31.3 48.6
63 054634F 0 4.5 3.5 94.9 50.9 46.4 2 53 32.6 38.1
64 080409F 0 4.5 3.8 89.8 54.4 39.4 3 89.7 52.5 41.5
65 328853F 0 4.5 3.1 88.6 36.3 59 1 87.8 47.8 45.5
66 331075F 2.35/12.4 2.35/9.22 3.2 0.4 0.06 9 1 4.2 3.3 132 72 45.5 2 79.4 35.7 55.1
67 322267F 0 4.8 3.4 107.5 47.4 55.9 1 60.9 25.5 58.2
68 322632F 0 4.2 3.2 78.4 41.4 47.2 2 84 46 45.2
69 327352F 1.8/14 2.5/15.8 3.1 0.3 0.12 10 1 4.1 3.2 74.2 41 44.8 3 86.8 51.5 40.6
70 322650F 0 4.6 3.3 97.3 44.1 54.7 2 73 43.7 40.2
71 433108D 0 5.2 4 129.5 70 45.9 2 68.2 44.8 34.3
72 347512F 0 4.8 3.6 107.5 56.3 47.7 2 73.7 42.1 42.9
73 288407F 0 4.5 3.4 92.4 47.4 48.7 2 63 33 47.6
74 287354F 0 5.7 4.5 163.1 94.3 42.2 3 48 27 43.8
75 291306F 0 4 2.9 71 32 55 1 82.6 40 54
76 256769D 2.3/17.8 2.8/18.2 2.4 0.3 0.04 6 1 4.6 3.4 97.8 47.4 51.5 2 87.8 48.9 44.3
77 286849F 0 6.2 4.9 194 115 41 3 188 108.8 42.1
78 299314F 4.7/14.8 5.6/18.3 5.4 0.6 0.14 28 2 4.4 3.1 87.8 37.9 56.8 1 92.2 41.1 55.4
79 299336F 0 4.1 2.9 73 33 55 1 78.4 37.3 52.4
80 309758F 0 5.6 4.2 155.8 80.1 48.6 2 76 39 48.7
81 761606D 0 4 2.8 70 29.6 57.8 1 89 44 50.6
82 981786A 0 4.8 3.6 109.6 52.8 51.8 2 82 34 58.5
83 316403F 0 5.6 4.4 151 87 42.4 3 76 44 42.1
84 316458F 0 4 2.9 70 32.2 54 1 87 38 56.3
85 040901F 0 4.9 3.3 112.8 44.1 60.9 1 85 41 51.8
86 077397F 0 4.1 3.1 56 21 62.5 1 93.8 32.2 56.4
87 89817F 0 4.3 3.2 83 39.4 52.5 2 47.9 16 66.5
88 354481F 0 4.3 3.2 81 38 53.1 2 81.6 46.8 42.6
89 354493F 0 5 3.4 112 54 51.8 2 79 35.55 55
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paper text:
INTRODUCTION
1MR is a frequent complication of coronary artery disease. It
was often under-rated because it is clinically silent, but with the use of echocardiography this complication
4is observed between 15%-20% after a myocardial infarction.
1
1When compared with patients without MR, the patients with acute myocardial
infarction and mitral regurgitation are older, more often in female and frequently
have a history of previous
ischaemic heart disease.2 Its presence and degree have major prognostic implications and underscore the
importance of its detection and quantification. Ischaemic mitral regurgitation can independently predict
cardiovascular death with a relative risk of 2.3 In a community trial, Bursi et al found that mitral
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regurgitation predicted heart failure as well as mortality among 1 month survivors independent of age,
gender, ejection fraction, and Killip Class.4 Even mild MR was shown to increase the mortality in SAVE trial
(Survival and Ventricular Enlargement) 3 hence, detection and quantification of MR is crucial. MR can be
estimated by different techniques on echocardiography. Color flow imaging allows an easy visualization of
MR, but was found to overestimate the MR.5 Mccully et al demonstrated that the same jet area
corresponds to smaller regurtitant volumes in functional MR as compared to organic MR.5 Doppler
echocardiography allows accurate assessment of regurgitant volume and effective regurgitant orifice and
thus provide the tools to reliably evaluate the prognosis and mechanism. Doppler methods are simple, fast,
reproducible and proven to be more reliable bur sparsely applied in routine clinical evaluation. Current
guidelines advocate quantification of MR by the measurement of
7vena contracta and proximal isovelocity surface area (PISA),
the most recommended quantitative approach whenever feasible. The semi-quantitative evaluation should
be abandoned.6 Echocardiography is the most common method to assess left ventricular systolic function.
It can efficiently predict the outcome and help in determining the treatment modalities like CRT-D
implantation etc. Routine 2D EF measurement has several limitations in AMI patients due to problems of
foreshortening and geometric assumptions.3D echo LVEF is much more accurate especially in presence of
regional wall-motion abnormalities as it does not have geometric assumptions and is found to have
comparable with present day ‘‘gold standard’’ for systolic function , cardiac MRI .7 It can automatically
calculate ejection fraction and left ventricular mass using the automated softwares, and is therefore more
reproducible. It is several folds accurate as compared to conventional echo. As there is no data for
prevalence of Mitral Regurgitation in Indian population, this study was undertaken. We evaluated the
prevalence and degree of Mitral Regurgitation in
4the acute phase and after 1
month of STEMI. AIMS AND OBJECTIVES PRIMARY AIM a. To study the following parameters
4in Acute ST Elevation Myocardial Infarction[STEMI] patients
i. Prevalence of mitral regurgitation[MR] by echocardiography in acute MI and during 1 month follow up ii.
3D-EF(ejection fraction) assessment SECONDARY AIM a. Correlation of 2D-EF, 3D-EF and MR in STEMI
patients REVIEW OF THE LITERATURE
13INTRODUCTION Mitral regurgitation (MR) is defined as systolic retrograde
flow from left ventricle (LV) to left atrium
(LA) because of pressure gradient between the two chambers. 8 The
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1term ischaemic MR does not necessarily imply the presence of true
myocardial ischemia, it is in fact an abridgment, characterizing a clinical situation
corresponding to chronic coronary artery disease with frequently a prior
history of one or more myocardial infarctions leading to progressive global or
regional pathological LV remodelling, usually in the absence of reversible
ischaemia. 9 Ischemic MR is a type of
secondary/functional MR due to coronary artery
1disease. Secondary MR is defined as functional MR, due to LV remodelling
by idiopathic cardiomyopathy or coronary artery disease.
8, 10
1It is important to distinguish between primary MR due to organic disease of
one or more components of the mitral valve apparatus and secondary MR
which is not a valve disease, but represents the valvular consequences of a LV
disease.
1There are however limitations in both terms: functional and ischemic. Indeed,
recent studies have demonstrated evidence of structural changes in the
mitral leaflets in response to tethering on them by LV pathological
remodelling. The leaflet adaptation includes enlargement and increased
stiffness.
11 PREVALENCE MR is a frequent accompaniment of ischaemic heart disease. Clinical presentation is
variable from silent to severe MR presenting with hemodynamic instability. It may be an incidental finding
on echocardiography or catheterization .3 Its importance was often underscored because of low murmur
intensity but with the use of echocardiography, MR is observed between 15%- 20% of patients with acute
myocardial infarction.1Different investigators have found variable incidence of MR in acute MI with the help
of different imaging modalities.Lehmann et al found 13 % incidence of mitral regurgitation early in the
course of acute myocardial infarction with the help of contrast left ventriculography.2 Tcheng et al reported
incidence of post-infarction mitral regurgitation was to be 17.9% of patients within hours of infarction.12
Indeed, when it is sought by doppler, MR has been reported to occur in up to 39% of patients with MI.
13,14 With the recent advances in non-invasive doppler echocardiography ,it is possible to accurately
assess the regurgitant volume and effective regurgitant orifice. Old age, diabetes, past history of MI,
severe CAD are more frequently associated with STEMI with MR than patients with STEMI without MR.2,
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12, 15 Its presence and degree have major prognostic implications and mandates its detection and
quantification. PATHOPHYSIOLOGY Normal mitral valve function depends on perfect delicate interplay
2between the mitral leaflets, the subvalvular- apparatus (which includes:
chordae tendineae and papillary muscle), the mitral annulus, and the left
ventricle.
Pathophysiology of ischemic MR is perplexing. Myocardial damage and LV dysfunction usually precedes
MR. Ischemic MR is characterized by normal leaflets and subvalvular apparatus and occurs due to
restricted motion of the leaflets. According to the Carpentier’s classification, ischaemic mitral regurgitation
is classified as type 3. 16 Given below is the classification based on motion of leaflet
6in relation to the mitral annular plane (figure 1) 1: normal leaflet motion.
Perforation of the leaflet due to traumatic injury or endocarditits, or annular dilatation, which may cause left
ventricular disease, is the cause of MR in type1. 2:
9excessive leaflet mobility accompanied by displacement of the free edge of
one or both leaflets beyond the mitral annular plane
into the left atrium.degenerative cardiac diseases may cause leaflet prolapse. 3: leaflet restriction. It is
further subclassified into 2 varities:
63a, where the restriction occurs throughout the cardiac cycle, i.e. both in
systole and diastole due to shortening of the chordae and/
2or leaflet thickening such as in rheumatic disease,
63b, where the leaflet restriction is seen in systole only (usually the result of
regional wall motion abnormalities seen in ischaemic mitral regurgitation).
16 Figure 1: Carpentier’s functional classification of Mitral Regurtitation17 Mitral Leaflet closure is mainly
an intricate interplay between the forces of tethering and ventricular forces (figure 2, 3). Increase in
tethering forces will not allow adequate
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1closure of the mitral leaflets. 8, 18 The
most frequent pattern seen is posterior infarction, more commonly trans mural,
1leading to local left ventricular pathological remodelling and thereby
contributing to posterior, apical and lateral displacement of the posterior
papillary muscle. As the papillary muscle extends non-extensible chordate to
both the leaflets, its displacement results in a more apical tethering of the
leaflets and their coaptation point, and a characteristic deformity of the
anterior leaflet which is described as the ‘seagull sign’. 8, 19 The tethering
process produces the shape like that of a tent between the annular plane and
the displaced leaflets. The tenting volume closely estimates the regurgitant
orifice area.8,
20 Tenting area is asymmetric in case of posterior infarction and regional remodelling,
1predominates on the posterior leaflet close to the medial commissure. It is
accompanied by decreased mobility of the posterior leaflet. In another subgroup
of patients
1with previous anterior infarction or both anterior and posterior infarctions,
1LV dilatation is more global, LV is more spherical, both papillary muscles are
displaced, the tenting area is symmetric, the regurgitant jet is central and the
contribution of annular dilatation and flattening is more important.
Second important determinant is decrease in ventricular closing forces, includes
1altered systolic annular contraction ,LV dysfunction ,reduced synchronicity
between the two papillary muscles and global LV dyssynchrony, especially in
basal segments.
8Factors aggravating the mitral regurgitation are
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3dilatation of the mitral annulus and the decrease in systolic annular
contraction, but isolated annular dilatation does not create functional mitral
regurgitation.
18 Figure 2: Left figure: Normal coaptation is seen. Right figure: tethering of leaflet due to papillary muscle
displacement and annular dilatation
3AO, aorta; Inf PM, inferior papillary muscle; LA, left atrium; LV, left ventricle;
MR, mitral regurgitation. (Reproduced from
3Levine RA, Hung J, Otsuji Y, et al. Mechanistic insights into functional mitral
regurgitation. Curr Cardiol Rep 2002; 4:125–9)
Occasionally, leaflet prolapse can occur as a result of fibrotic elongation of papillary muscle which may be
followed by an event such as myocardial infarction and this can result in MR. (Carpenters’ Type 2). The
consequences of MR depend on the following underlying factors a. Severity of regurgitation b. LA
compliance c. LV-LA gradient (the driving force) d. Duration of the lesion Acute MR can occur secondary
to two rare causes:
1rupture of a papillary muscles resulting from acute myocardial infarction and
transient active ischemia leading to true ischemic MR. The
1rupture of a papillary muscle, more often in
the location of
1head of the posteromedial papillary muscle, is a catastrophic complication of
actual MI
1with a high mortality if emergency surgery is not
done.8, 21 In majority of patients with chronic ischemic MR complicating left ventricular dysfunction and
heart failure, LA is enlarged and has a greater compliance with low driving force. The volume overload
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resulting from MR contributes to a vicious cycle : the more remodelling of left ventricle, the more severe
MR begets MR, so greater the severity of MR, larger the volume overload on LV which finally leads to LV
remodelling.LV becomes more and more dilated and spherical in accordance to laplace law, which further
propentiates the MR. Despite a reduction in LV impedance, LV wall stress increases ,finally translating into
LV dysfunction.22Chronic ischaemic MR finally leads to development of
1pulmonary arterial hypertension. Another important feature of ischaemic MR is
its
dynamicity. 23 The
1degree of MR is best quantified by the effective regurgitant orifice (ERO) area.
24 The regurgitation area
keeps on changing throughout the systole due to dynamic changes in transmitral pressure, though it is of
lesser importance in midsystole when compared to other phases of systole.25,26 ERO is load dependent,
therefore affected by daily activities. Another evidence of the dynamicity of ischaemic MR ↑ tethering
forces ↓ Ventricular forces (left ventricle dysfunction) Ischemic MR LA Enlargement ↑ Left Ventricular wall
stress AF, PAH left ventricle Remodelling (Annular dilation, papillary muscle displacement) Figure 3:
Pathophysiology
1of Ischaemic MR is a reduction of regurgitant volume related to a reverse LV
remodelling obtained by appropriate medical treatment.
27 Dynamic nature of MR can be very well
1appreciated during an exercise doppler echocardiogram. 28 The degree of
MR seen at rest is not related to exercise-induced changes in ERO area or
regurtitant volume.
29 Exercise-induced changes are quite variable in different individuals. In some individuals
1with moderate or severe MR at rest, a decrease in ERO area can be
observed with exercise and usually results from contractile reserve of the LV,
in particular of the postero-basal segment and/or a reduction in intra LV
dyssynchrony.30 Around
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130% of these patients develop an increase in
the severity of regurgitation
1and in systolic pulmonary artery pressure during exercise. The degree of
exercise-induced increase or decrease in MR relates to changes in valve
deformation, LV remodelling and
papillary muscles synchronicity. DIAGNOSIS AND QUANTIFICATION Clinical examination in ischaemic MR
may reveal a regurgitant murmur of low grade or may even be silent or inaudible .It is an insensitive
method for ischaemic MR diagnosis due to subtle or near normal auscultatory findings in many patients.
This can be explained from the fact that cardiac output is low, LV contractility is compromised and atrial
pressure is high thereby they cause lower regurgitant volume, consequently low grade murmur in ischemic
MR compared to organic MR. There is no correlation between intensity of murmur and severity of
ischaemic MR. The
1diagnosis of ischaemic MR is usually made by using imaging
modalities like doppler echocardiography. Doppler echocardiography is a useful tool in diagnosis and is
superior to other techniques like contrast ventriculography. Importance of doppler echocardiography in
routine clinical practice is undisputed. Clinically subtle findings like low intensity murmurs
3should always lead to a careful echocardiographic examination. Quantification
of MR is
also crucial. Echocardiography plays a key role not only in diagnosis of regurgitant lesion but also in the
assessment of the mechanism and the severity of MR. It also has a role in determining treatment options
as it helps in determining the feasibility of valve repair versus replacement. Assessment of Mitral
Regurgitation by echo can be (a) qualitative (b) quantitative. QUALITATIVE METHODS
2Colour flow imaging Colour flow imaging is the most widely used method to
assess MR severity
echocardiographically .32 This measurement is poorly reproducible and influenced by various factors.
Though it allows an easy visualization of the regurgitation and frequency of MR, it has major limitations in
assessing the severity of MR. 5, 33 It tends to overestimate the severity of regurgitation. It is generally
assumed that with increasing MR, the
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5size and extent of the regurgitant jet in LA
is increased.
2Larger colour jets extending deep into LA represent greater severity of MR than
small thin jets that appear just beyond the mitral leaflets. However, the jet
size
may be influenced by other factors such as technical and hemodynamic influences and therefore caution
must be exercised in interpretation of jet severity based on jet size. For the same severity of MR ,
5patients with increased LA pressure, enlarged LA or wall hugging eccentric
jet may show
2smaller jets area when compared with normal LA pressure, size or with central
jets.
6
2In acute MR, even centrally directed jets may be misleadingly small.
Nevertheless,
2a large eccentric jet adhering, swirling and reaching the posterior wall of the
LA
favours significant MR and smaller thin jets appearing
5just beyond the mitral leaflets usually
is an indicator of mild MR. Continous Wave Doppler of MR jet
5Continuous wave doppler of mitral regurgitation jet
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is another qualitative parameter which is used to measure the severity of mitral regurgitation.
2The signal intensity (jet density) of the CW envelope of the mitral regurgitant
jet can be used as a qualitative indicator to mitral regurgitation severity. A dense
triangular mitral regurgitation signal with a full envelope indicates severe mitral
regurgitation than a faint signal.
2Truncated (notch) envelope with a triangular contour and an early peak
velocity (blunt) indicates elevated LA pressure or a prominent regurgitant
pressure wave in the LA due to severe MR. In case of eccentric mitral
regurgitation; it may be difficult to record the full CW envelope of the jet,
while the density may be used as indicator for assessing the severity. SEMIQUANTITATIVE MEASURES
1The semi-quantitative evaluation of regugitant jet area should not be
used.6 It is recommended that these measures should only be used for diagnosing mitral regurgitation,
and not to quantify the severity of MR.
2A more quantitative approach is recommended when more than a small central
MR jet is seen. Vena contracta width (VCW) The vena contracta is the narrowest
portion of the MR jet downstream from the orifice; it reflects the effective orifice
area.
34-36 Whenever feasible measure the dimensions of vena contracta, which can help in quantification of
MR. Using a careful probe angulation and
2adapted Nyquist limit (colour Doppler scale) (40–70 cm/s), the
2vena contracta is typically imaged in a view perpendicular to the commissural
line (e.g. the parasternal long-axis or the apical four chamber view)
to
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2identify the neck or the narrowest portion of the jet. This narrowest doppler
colour sector scan can be coupled with the zoom mode to improve resolution
and
for more accurate measurement (Figure 4). It is recommended that if possible averaged measurements
over at least three beats should be taken and measurements should be taken from two orthogonal planes.
A vena contracta, < 3 mm is considered as an indicator of
2mild MR whereas a width ≥7 mm defines severe Mitral Regurgitation, values
in between 3 to 7 mm are ambiguous and need further confirmation by a more quantitative method.6 The
2concept of vena contracta is based on the assumption that the regurgitation
orifice is almost circular,
this assumption holds true in cases of organic MR but in functional MR the results may not be accurate as
the orifice may be non circular and
5elongated along the mitral coaptation line.
37, 38 Thus, it could look
2narrow in four-chamber view and broad in two-chamber view. Conventional
2D colour Doppler imaging does not provide appropriate orientation of 2D
scan planes to obtain an accurate cross-sectional view of the vena contracta.
The vena contracta can be classically well identified in both central and
eccentric jets. In case of multiple MR jets, the respective widths of the vena
contracta are not additive. Such characteristics may be better appreciated
and measured on 3D echocardiography. In cases of functional MR, a mean
vena contracta width (four- and two chamber views) has been shown to be
better correlated with calculation done using the 3D vena contracta.
41 3D echo
5assessment of the vena contracta is
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not used routinely and currently it is used for research purposes.
2A mean value >8 mm on 2D echo has been reported to define severe MR for
all
5aetiologies of MR including functional MR,
though it needs confirmation in further studies.39 Figure 4. Measurement of Vena contracta width in Mitral
Regurtiation. Pulmonary venous flow Doppler It is an additional parameter for evaluation of MR severity.
Normally, if there is no diastolic dysfunction in venous flow Doppler we get
2a positive systolic wave (S) which is followed by a smaller diastolic wave (D).
As the
2severity of MR increases, there is a blunting of the S wave velocity.
Systolic blunting or systolic flow reversal will be seen in moderate and severe MR respectively.
QUANTITATIVE METHODS
5Doppler volumetric method Doppler volumetric method can
calculate regurgitant volume by finding the difference between measured mitral and aortic stroke
volume.43.It can be inferred using 2D echocardiograph by calculation of LVEDV and LVESV which are
calculated using biplane method of disks. 42 Same jet areas correspond to smaller RVol in ischemic MR
than in organic mitral regurgitation. However, this method is cumbersome and time consuming. It is not
recommended as first line investigation for quantification of regurgitant volume. Flow Convergence Method
Flow-convergence method is the most frequently quantitative method for estimation of MR in current
practice.44It is based on law of conservation of flow; its basis lies in the modified form of continuity
equation. It enables the measurement of ERO area and regurgitant volume with precision.45 As the flow
convergence is proximal to the regurgitant orifice it forms the basis of analysis.46
2The apical four-chamber view is classically recommended for enabling good
visualization of the proximal isovelocity surface area (figure 5). However,
in
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5anterior mitral valve prolapse the calculation of
PISA should be done in the parasternal long- or short-axis view. By lowering the image
2depth and reducing the Nyquist limit to 15–40 cm/s,
flow velocity at a hemispheric surface proximal to regurtitant orifice can be determined.6 The
2radius of the PISA is measured at mid-systole using the first aliasing.
Regurgitant volume (R Vol) and effective regurgitant orifice area (EROA) are
obtained using the standard formula.
Regurtitant flow = 2 Π (radius of the flow convergence) 2 x aliasing velocity ERO is the ratio of regurgitant
flow /peak mitral regurgitant velocity Regurtitant volume (RVol) is calculated as product of ERO and MR
TVI.
2Qualitatively, the presence of flow convergence at a Nyquist limit of 50–60
cm/s is an indicator to the presence of significant MR. 6 Grading of organic MR
6 Mild Moderate Severe EROA (mm2) <20 20–29; 30–39
2≥40 R Vol (mL) <30 30–44; 45–59
≥60 Moderate regurgitation group can be further classified
2into ‘mild-to-moderate’ (EROA of 20–29 mm2, R Vol of 30–44 mL) and
‘moderate-to-severe’ (EROA of 30–39 mm2 or R Vol of 45–59
2mL). In ischaemic MR, the thresholds of severity, which are of prognostic
value, are 20 mm2 and 30 mL, respectively. 47 EROA is the most robust
parameter as it represents a marker of lesion severity. A large EROA can lead
to large regurgitant kinetic energy (large R Vol) as well as to potential energy,
with low R Vol but high LA pressure.
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Ischemic MR Low Risk EROA<20mm2 RVol<30ml High Risk EROA>20mm2 RVol>30ml Figure 5: Ischaemic
MR Grading (6, 48) This method is simple, fast, and reproducible and has been validated by multiple
investigators.46; 49It precisely calculates the RVol, which indicates the volume overload induced by MR,
and the effective regurgitant orifice (ERO), which delineates the severity of anatomic lesion. PISA radius
Figure 5. Determination of radius of proximal isovelocity surface area (PISA) in ischaemic Mitral
Regurgitation.
1There are several limitations of the proximal isovelocity surface area (PISA)
approach. 8,46 First, the PISA radius changes during systole is larger in early
and late systole, and smaller in midsystole when the LV pressure is maximal. 50
Ideally, the PISA radius should not be measured at only one time point, but
averaged through systole. Second, for an accurate measurement, the flow
convergence should be hemispheric.
In cases of functional MR, the
1flow convergence—a three-dimensional structure—is frequently hemielliptic
(Fig 6), implying an underestimated calculation of ERO and regurgitant
volume,
particularly
2when the ratio of long-axis length to short-axis length of the 3D regurgitant
orifice is >1.5.
38, 51-52 Third, multiple jets can
1be present; the addition of several flow-convergence regions has not been
validated.
Fourth, it is more accurate for central jet. It
2may not hold for eccentric jets, several jets, or complex or elliptical
regurgitant orifices. Practically, the geometry of the PISA varies based on the
shape of the orifice and mitral valve leaflets surrounding the orifice.
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Figure 6: 3Dimensional
5shape of the convergence flow in (a) functional
MR (b) organic MR (Reproduced from EHJ guidelines
1for the assessment of the valvular regurgitation
2010)
1Thus, practically, the most reliable calculation of regurgitant volume and
ERO area is the averaging of the quantitative doppler and the PISA methods
.However, this approach is time consuming.8 Invasive assessment Mitral regurgitation could be assessed
by invasive ventriculography. Some schools of thought have considered Left ventriculography
3as the reference methodology for assessment of mitral regurgitation. However
this
method of grading of MR is also subject to limitations and cannot thereby be considered gold standard
because of influence of loading conditions affecting the MR severity. Comparatively, Quantitative Doppler
echocardiography is non invasive and also provides more objective data for grading and prognostic
information about regurgitation than ventriculogram.53 PROGNOSIS The presence of ischaemic MR
4is an important indicator for long term
morbidity as well as mortality. It
4is an independent risk factor for the same. The presence of
ischaemic MR may result from acute infarction resulting in regional left ventricular dilation and consequent
loss of contractile mechanism or in some instances it may be a previously existing lesion which went
undiagnosed. Several studies have clearly shown that ischaemic mitral regurgitation can predict
cardiovascular mortality independently.2-4,8, 12, 54 Relative risk was found to be quite variable ranging
from 1.48 - 7.5.8
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1Worse long term prognosis was seen in patients presenting with non ST
elevation
myocardial infarction .55 A community based
1study has also confirmed the prognostic importance of ischaemic MR
among one month survivors of MI:
1its presence is associated with a three-fold increase in the risk of heart
failure and a 1.6-fold increased risk of death at 5-year follow-up, independent
of LV ejection fraction, Killip class, age and gender.
4,8 Barzilai et al found that AMI patients with a murmur suggestive of MR had a 12-month mortality of 36%
compared with 15% for patients without an MR murmur. 56SAVE study investigators also showed that mild
MR was associated with high mortality. Greater the severity of mitral regurgitation, worser was the
prognosis.48 Even uncorrected mild MR, as well as moderate to severe ischaemic MR is found to be
associated with higher mortality on long term.
1However, the severity of ischaemic MR tends to follow the severity of the LV
dysfunction causing the MR; the worse the MR, the worse the LV functions. Till
date, there are no studies
to prove that ischaemic MR is a predictor of long term prognosis irrespective of severity of LV dysfunction
present.8 No studies have proved that correction of mitral regurgitation will mitigates the long term mortality
independent of left ventricular systolic dysfunction8 Though small case series has shown that coronary
revascularisation in acute MI has reduced the severity of MR in selected patients, it tend to persist in >
50% of patients of MI on follow up.12 Therefore, even coronary revascularisation may not halt its
progression during long term. Prognosis is also found to be related to the dynamicity of component of
ischaemic mitral regurgitation. A 5
1fold increase in the relative risk of death with an exercise-induced increase
of ≥13 mm2 of the ERO area
was found.8, 57 It is the best predictor of hospitalisation and cardiovascular morbidity as compared to
severity of mitral regurgitation at rest. Its deleritious effects are related to several factors like sudden
increase in R Vol (regurgitant volume) and with rapid QRS widening due to increases in
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1ventricular wall stress leading to worsening LV
dyssynchrony.58 In
1patients with LV systolic dysfunction, acute pulmonary oedema
which may develop due to sudden worsening of dynamic MR leading to acute increase in left atrial
pressures.8, 59 Greater exercise-induced regurgitant volume and systolic pulmonary arterial pressure may
cause exertional dyspnea.60 Around 20% may have
1an improvement in the severity of ischaemic mitral regurgitation during
exercise, who have a favourable long term prognosis.
57 This is thought to happen
1in patients with contractile reserve in posterior
segment.29 MANAGEMENT Numerous treatment options have been proposed but the treatment of
ischaemic mitral regurgitation still remains a complex issue and needs further research and trials to find an
ideal treatment modality with long term benefits. In current clinical approach at most places ring
annuloplasty is preferred treatment modality. However, long term benefits of this technique remains
obscured as it has no role in correction of local alteration due to left ventricular remodelling. Medical
Management Standard anti-failure medications such as angiotensin-converting enzyme (ACEI) inhibitor or
ARBs if the ACEI is not well tolerated), aldosterone antagonist and beta-blockers .8, 61 It may help in
alleviating the severity of mitral regurgitation by producing reverse left ventricular remodeling.8, 62 Cardiac
resynchronization therapy Though biventricular pacing per se is not an treatment modality for ischaemic
mitral regurgitation, it is an indication to consider CRT in patients of ischemic MR with reduced left
ventricular ejection fraction ,functional class III or more even with medical treatment and ecg showing QRS
of more than 120 ms.63 Cardiac resynchronization therapy resynchronize the papillary muscles and
increase the closing force which helps in immediate reduction in MR.8,64- 65 There is further more
reduction in the severity of MR in long term that is after few weeks or months as it plays a role in LV
reverse remodelling, through a reduction in tethering .It can also reduce dynamic MR.66 Magnitude of MR
induced by exercise attenuate significantly in parallel to reverse Left Ventricular remodelling over a period
of three months and result in improved cardiopulmonary performance.8, 67 Despite a reduction in the
severity of MR, residual MR frequently persists. Immediate recurrence of MR has been seen post
withdrawal of CRT due to dyssynchronization of the papillary muscles leads to. 68-70 Percutaneous
coronary revascularization It may help in reducing the severity of mitral regurgitation at rest as well as
during exertion in the subset where it is directly induced by ischaemia. .8 Surgical Management Surgical
approach for management of ischemic MR can only reduce its severity, not eliminate it completely.
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Coronary artery bypass grafting by itself is regarded insufficient in correction of MR. 71 Persistence of
even little residual mitral regurgitation postoperatively has been shown to be associated with higher
mortality 72 With the use of an undersized prosthetic (preferably two- sizes) ring 73,
1reduction in LV volume has been seen and even a small increase in LV
ejection fraction
has been documented , 74 but the long-term benefits could not be proved.75,76 Several studies have
shown that long-term outcomes in terms of survival benefit or functional outcome is questionable by
combined surgery. 75,77-78 In a recent randomized control trial it has been shown that mitral valve repair
done along with CABG was associated with improvement of NYHA class, LVEF, and reduction in left
ventricular diameter, left atrial size and PAP(pulmonary artery presence) .79It
1was not powered enough to analyse the effect on
mortality . To conclude it may be said that fixing some valves may help, but it is difficult to identify which
ones.80 Recently published
1meta-analysis showed that mitral valve repair for ischaemic mitral regurgitation
is associated with better
survival compared with MVR (mitral valve replacement). 81 The European Society of Cardiology
1guidelines recommend that patients with severe ischemic mitral regurgitation
(ERO area ≥20
mm2) undergoing
1CABG should be treated by combined surgery (class I, level of evidence
C). 8,82Mitral valve repair may be considered
1in symptomatic patients with severe mitral regurgitation who cannot be
revascularized is questionable
(class IIb).82 Mild mitral regurgitation should be managed conservatively. Due to the lacuna of well defined
guidelines and evidence, the management of ischemic MR should be individualized. Assessment of
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myocardial viability, especially in region of posterior basal wall, inducible ischemia and the dynamic
component of MR aids in decision making. Biphasic response or regional contractile reserve during stress
testing usually have exercise-induced reduction in mitral regurgitation, can be help decision making.
Patients with exercise-induced increase in effective orifice area area ≥13 mm2 could be taken up for
combined surgery. Severity of MR is always underestimated even with intra-operative TEE.
Pharmacological measures like phenylepherine or rapid fluid challenge may be used to assess the
ischaemic MR.83 Parameters like grossly dilated left ventricle, multiple regurgitant jets , systolic sphericity
index, wall motion score index, ESV( end-systolic volume), severe MR, >2.5 cm2 systolic tenting area, ,
large angle (≥45°) of the posterior leaflet, >1 cm distance between coaptation point and mitral annulus are
recognized as predictors of bad outcome of procedures like mitral valve repair by annuloplasty .84-86
Several adjunctive techniques have been proposed like chordal cutting, internal direct repositioning or
external repositioning of the displaced papillary muscle. 8, 87 However, they are not yet clinically approved
for routine management of ischaemic mitral regurgitation. PERCUTANEOUS REAPIR Percutaneous edge-
to-edge Alfieri procedure has been used for the treatment of MR due to either ischaemic or organic cause.
In it, the central parts of both mitral leaflets are apposed producing a double orifice. 8, 88 Many
researchers have developed the devices which can be delivered in coronary sinus and reduce the severity
of mitral regurgitation by pushing the PML forward.89-90 Long term effects of these devices needs to be
studied. FORTHCOIMG THERAPIES Future targets like transplanting autologous myoblast has potential
proven to cause localized LV reverse remodelling and appears to be a promising approach in decreasing
ischaemic MR. More understanding of our concepts of leaflet adaptation in LV dysfunction can help us in
developing potentially better therapies in future. 91 3D EF Measurement in Myocardial Infarction
Echocardiography is the most common method to assess left ventricular systolic function. It can efficiently
predict the outcome and help in determining the treatment modalities like CRT-D implantation etc. Routine
2D EF measurement has several limitations in AMI patients due to problems of foreshortening and
geometric assumptions.3D echo LVEF is much more accurate especially in presence of regional wall-
motion abnormalities as it does not have geometric assumptions and is found to have comparable with
present day ‘‘gold standard’’ cardiac MRI .(5) It can automatically calculate ejection fraction and left
ventricular mass using the automated softwares, and is therefore more reproducible. It is up to 3 times
more accurate than 2DE LVEF.7 Figure 7.Measurement of 3D EF in echocardiography through Q lab
analysis DESIGN AND METHODOLOGY Study Design:
11This is a single centre prospective observational study
done in the department of Cardiology, Christian Medical College (CMCH), Vellore. SETTING
11Study was done in the Cardiology department of Christian Medical College
and
Hospital, a tertiary care hospital in South India.119 consecutive patients with STEMI were assessed for
mitral regurgitation using various echocardiographic parameters. STUDY PARTICIPITANTS Inclusion
criteria: All patients older than 18 yrs old, who sustained STEMI between September 2011 to August 2012.
Exclusion criteria: Patients were excluded from the study if they had 1. Rheumatic heart disease 2.
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Persistent arrythmias 3. Known coronary artery disease(CAD) 4. Cardiogenic shock 5. Trivial MR Methods:
1. Demographic and clinical profile of patients were collected were collected once they consented 2. All
patients underwent echo once they were stable during index admission. Mitral regurgitation quantified
using jet width[vena contracta], jet area
7and proximal isovelocity surface area(PISA)
,if central jet is present 3. Left ventricular
7ejection fraction were assessed by both Simpson’s method
as well as 3D echocardiography STATISTICAL ANALYSIS Statistical analysis was done using commercially
available statistical software (‘IBM SPSS software version 15’, Illinois, Chicago). All
10continuous variables are expressed as mean ± SD and categorical variables
are expressed as number (percentages). Independent samples T test was used
for comparative analysis of
two groups with a normally distributed continuous variables. Comparison of categorical variables was done
using Chi square test. Pearson correlation coefficient was used to analyze the correlation between two
continuous variables with a normal distribution. Comparative
8analysis was performed by one way analysis of variance (ANOVA). A p value
less than 0.05 was considered statistically significant for all test results.
RESULTS 1. STUDY PROFILE AND
BASELINE CHARACTERISTICS
4A total of 119 patients of STEMI were evaluated
for ischaemic MR during the study period.
4Mean age of patients in the whole study population was
53.42 ± 11.47 years. Majority patients (57.1%) were found to be in the age group of 40-59 years, with least
number was in >80 yrs (2.5%).10.9% patients were young, <40 years having MI. Number of males
outnumber within each group.Ratio of Males: Female is 96:23. 31.9%(38) of the patients has type 2
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diabetes mellitus,98.3%(117) of patients had dyslipidemia, 37.8(45) % of the patients had hypertension
,54.6% (65) were obese , 47.1%(56) were current smoker and 13.4%(16) had positive family history of
coronary artery disease(CAD). On an average all patients were had at least 2 risk factors. Baseline
characteristics of both groups with Anterior wall MI (AWMI) and Inferior wall MI (IWMI) were comparable
without any significant statistical difference except baseline 2D EF, which was higher in IWMI group (table
1). Patients presenting with AWMI were having slightly higher proportion of hypertension, though it was
statistically insignificant. Characteristic AWMI IWMI p value Age 52.30±11.11 54.58±11.81 .281 Male
47(78.3%) 49(83.1%) .515 Female 13(21.7%) 10(16.9%) .515 Diabetes 19(31.7%) 19(32.2%) .85
Hypertension 27(45%) 18(30.5%) .103 Smoking 29(48.3%) 27(45.8%) .779 Dyslipidemia 59(98.3%)
58(98.3%) .990 Obesity 35(58.3%) 30(53.1%) .293 Positive Family History 10(16.7%) 6(10.2%) .299
Baseline 2D EF 44.94+7.5 50.7+7.4 .000(significant) Baseline 3D EF 45.42+8.5 46.96+8.6 .33 Table
1.Baseline characteristics of patients according to the type of STEMI 2. Prevalence of MR 27(22.7%)
patients were found to have MR during index admission for MI (Figure 8), out of which 24(88.9%) had mild
MR and 3(11.1%) had moderate MR based on quantitative measurements. None of the patients were
found to have severe MR. Mean Vena contracta (VC) in mild and moderate MR patients at presentation
were 2.91±0.94 and 3.54±0.25 respectively. Mean PISA radius, effective regurtitant orifice area (ERO) and
regurgitation volume in mild MR patients at presentation were 0.315±0.08, 0.05±0.03 and 7.07±3.65
respectively (table 2). MR VC(mm) PISA ERO(cm2) MR radius(cm) Volume(ml) MILD(n=24) 2.91±0.94
MODERATE(n=3) 3.54±0.25 AFTER 1 MONTH MILD(n=12) 2.97±0.55 MODERATE(n=2) 4.8±8.5
0.315±0.08 0.05±0.03 7.07±3.65 0.44±0.06 0.10±0.06 30.33±7.77 0.38±0.81 0.05±0.03 6.9±3.17
0.55±0.07 0.125±0.02 27±1.41 Table 2.Quantitative echocardiographic parameters of MR at presentation
and after 1 month Mean age of patients presenting with ischaemic MR at onset was 59.2 ± 10.82(figure 9),
population includes 74.1% males (20) and 25.9 %( 7) females. Majority of patients presenting with MR at
admission were in the age group of 60-79 years (figure 9).Among the patients having MR at admission
included 48.1%(13) type 2 diabetics, 100%(27) dyslipidemics, 33.3 % (9) hypertensive’s, 44.4% (12)
obese, 44.4 %(12) current smoker, 22.2%(6) had AWMI, 77.8%(21) had IWMI and none had a positive
family
4history of coronary artery disease (CAD).
Though there was trend towards females being more commonly associated with MR, it was found to be
statistically insignificant (figure 10). None of the risk factors predicted of onset of MR in STEMI patients at
admission and during follow up on statistical analysis except age, diabetes and site of STEMI(Table
3).IWMI patients were more likely to develop MR at presentation (table 3).Male gender was found to have
higher prevalence of absence of MR during follow up. MR 22.7 PRESENT 77.3 ABSENT Figure
8.Prevalence of MR at admission 60 Number of STEMI patients 50 40 30 MR ABSENT 20 MR PRESENT 10
0 20-39 40-59 60-79 >80 Age groups Figure 9.Prevalence of MR according to the age groups 100 100 90
80 79.2 77.8 78.6 76.1 80 70 65.2 65.8 60 50 40 30 20 20.8 34.8 34.2 22.2 21.4 23.9 20 PRESENT
ABSENT 10 0 0 Figure 10.Proportion of baseline risk factors of patients with and without MR During follow
up after 1 month, MR was found to be present in 15.7% of patients despite a dropout of 30(25.2%)
patients (figure 11).MR continue to persist in 10.1 %( 9) patients with improvement in severity in 13.5 %(
12) and new onset in 5.6 %( 5) patients (figure 12).Among 14 patients who were having MR at follow up,
3(21.4%) had AWMI and 11(78.6%) had IWMI at baseline. None of the baseline characteristic was found to
be predictor of mitral regurgitation during follow up (table 3) excluding sex and site of STEMI.AWMI and
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males tend to have lesser prevalence of mitral regurgitation at follow up (table 4). IWMI patients continue to
have higher incidence of Mitral Regurgitation which was persistent and also developed new onset MR, but
it was not statistically significant (p-0.647).Females have higher prevalence of Mitral Regurgitation during
follow up visit(table 3).None of the patients with positive family history had Mitral Regurgitation at onset.
Development of MR in STEMI patients was not influenced by the treatment modality used (figure 13). MR
15.7 84.3 ABSENT PRESENT Figure 11.Prevalence of MR after 1 month 14 13.5 12 10.1 Number of
patients 10 8 6 4 5.6 2 0 MR Figure 12.Profile of MR after 1 month Proportion of patients having greater
severity of MR after 1 month was found to be slightly higher, despite being reduction in absolute number of
patients having moderate MR (figure 14).Initially, 3(11.1%) patients had moderate MR, but at 1 month, only
2 patients had moderate MR. IWMI patients were found to have higher prevalence of MR (figure 15). 60 51
50 Number of patients 40 31 MR PRESNT 30 MR ABSENT 20 11 14 10 10 2 0 THROMBOLYSIS PRIMARY
PTCA OTHERS Figure 13.Prevalence of MR in relation to treatment strategies Characteristic Baseline MR
p value MR at 1 p value month Age (yrs) Group 1 (20-39) 1(3.7) 2(14.3) Group 2 (40-59) 11(40.7) 0.024*
5(35.7) 0.132 Group 3 (60-79) 14(51.9) 7(50) Group 4 (≥ 80) 1(3.7) 0(0) Sex Male(96) Female(23)
20(74.1) 7(25.9) 0.323 9(64.3) 5(35.7) 0.007* Site of STEMI AWMI(60) IWMI(59) 6(22.2) 21(77.8) 0.001*
3(21.4) 11(78.6) 0.03* Diabetes(n=38) 13(48.1) 0.04* 5(35.7) 0.612 Hypertension(n=45) 9(33.3) 0.585
4(28.6) 0.615 Smoking(n=56) 12(44.4) 0.757 5(35.7) 0.210 Dyslipidemia(n=117) 27((100) 0.44 14(100)
0.539 Obesity(n=65) 12(44.4) 0.36 5(35.7) 0.257 Positive Family History(n=16) 0(0) 0.02* 1(7.1) 0.458
Baseline 2D EF 48.17±8.93 50.2±8.6 Baseline 3D EF 46.24±7.68 0.769 50.37±8.61 0.216 Reperfusion
modality Thrombolysis (n=45) Primary PCI (n=62) Miscc(n=12) 11(40.7) 14(51.9) 2(7.4) 0.744 8(57.1)
6(42.9) 0(0) 0.134 Table 3.Comparison of various variables with MR at onset and during follow up
*statistically significant MR Sex Total p value 1(Male) 2(Female) Absent Number of patients 69 7 76
(88.5%) (58.3%) 84.4% 0.019* Present Number of patients 9 5 14 (11.5%) (41.7%) 15.6% Total Total no.
78 12 90 % within sex 100.0% 100.0% 100.0% Table 4. Association of sex with the prevalence of Mitral
Regurgitation at 1 month Severity Baseline MR MR at FU Mild 24(88.9) 12(85.7) Moderate 3(11.1) 2(14.2)
Severe - - Figure 14.Prevalence of severity of MR at onset and after 1 month 100% 90% 80% 70% 38 60%
53 MR ABSENT 50% MR PRESENT 40% 30% 20% 21 10% 7 0% AWMI IWMI Figure 15.Prevalence of MR
in relation to type of MI 3. Correlation among 2D and 3D EF in STEMI Mean 2D EF in AWMI group at
presentation was 44.94% ± 7.5% and in IWMI group was slightly higher 50.7% ± 7.4.4%.LV systolic
functions was found to be better in IWMI patients on presentation. After 1 month, there was an increase in
2D EF by 6.9%(51.83±8.06) in AWMI group and negligible change in IWMI group (51.05±8.4).2D EF was
found to strongly correlate with 3D EF at admission and during follow up irrespective of type of STEMI
(table 5), though poor image quality was one of the hindering factor in some of the patients. Figure 14
shows the scatter plot displaying the distribution of 2D and 3D EF at baseline. 2D and 3D EF Correlation p
(2 tailed) coefficient, r At admission 0.525 0.01 At 1 month 0.609
40.01 Table 5.Correlations of 2D and 3D
EF at admission and after 1 month 70 y = 0.5651x + 19.179 60 R² = 0.2756 50 Baseline 3D
14EF 40 30 20 10 0 0 10 20 30 40 50 60
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70 80 Baseline 2D EF Figure 16.Scatter plot showing relationship of 2D-EF and 3D-EF at admission
(Pearson correlation coefficient r, 0.525) *
12Correlation is significant at the 0.01 level (2-tailed). DISCUSSION The
present study
is a prospective observational study which evaluated the prevalence of functional (ischaemic) mitral
regurgitation in patients with STEMI at presentation and during 1 month of follow up.
4Mean age of patients was 53.42 ± 11. 47 years
with majority of them being males (83%). Most common age group was found to be 40-59 years (57.1%),
with least patients in >80 yrs (2.5%).10.9% patients had MI in young (<40 years).Our results are found to
be similar as observed in a large retrospective analysis by Brijesh et al92 done in our institute. Most
common risk factor was found to be dyslipidemia(98.3%) , followed by obesity(54.6%),smoking
(47.1%),diabetes(31.9 %), hypertension (37.8%) and positive family history of coronary artery
disease(13.4%). This data is different from create study where diabetics 34% had diabetes; 37.7% had
hypertension; and 40.2% were smoker.93 All patients were having multiple coronary risk factors.LV systolic
function was found to be better in IWMI patients at presentation as lesser territory was compromised by
ischaemia. Similar results were observed by Darbar et al and our findings are consistent with it.94 With
anterior infarction, the injury is exclusively in the left ventricle, whereas inferior infarction is associated with
injury to both ventricles, causing less impairment of left ventricular function despite an equivalent overall
myocardial insult. After 1 month, there was a trend in the increase in 2D EF by 6.9% in AWMI group due to
revascularisation therapy.95 MR was found in 22.7% at presentation of STEMI in our study population,
which is in accordance with older studies including angiographic ones (table 5). It was found to be higher in
older age group, diabetics and IWMI patients at the onset, which was consistent with previous studies.2,
12, 15 There was a trend toward an excess of women in the MR group, though it was not statistically
significant due to under representation of females in present study. Similar data on the demographics of
MR after AMI have been presented earlier by Lehmann, Tcheng, and Barzilai.2, 12, 15 IWMI involves the
posterior wall of LV leading to left ventricle remodelling and distortion. This result in apico-lateral as well as
posterior displacement of papillary muscle, which in turn leads to apical displacement of mitral leaflet
coaptation point, producing the ischaemic mitral regurgitation.8 Mostly patients had mild MR and none had
severe MR which is possibly due to exclusion of very sick patients like cardiogenic shock. During follow up
after 1 month, MR was found to be in 15.7% of patients despite a dropout of 30(25.2%) patients. Some
patients with MR tend to improve with the resolution of acute ischaemia due to revascularisation as well as
favourable LV remodelling and improvement in LV systolic function, while some had deteriorated with
worsening mitral regurgitation due to adverse left ventricular remodelling with passage of time after STEMI.
Treatment modality used didn’t influence the development of MR as shown earlier by Tcheng JE et al.
Acute reperfusion with thrombolysis or angioplasty did not reliably reverse valvular incompetence as seen
in earlier observational studies. None of the baseline risk factor except diabetes, territory involved and
older age group ,can reliably predict the development of MR at onset and left ventricle systolic function,
though this study was not powered enough to study those predictors. IWMI patients tend to have higher
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prevalence of MR during the STEMI as well as during follow up secondary to tethering effect on the mitral
valve leaflet which may be a harbinger of chronic MR later on. Treatment modality didn’t influence the
severity of MR in STEMI patients. Author Year No of Modality used Prevalence patients of MR (%) Barzilai
B et al15 Tcheng JE et al12 1988 1480 Echo 39 Lehmann KG et al2 1992 1480 Echo 17.9 1992 206 LV
ventriculography 13 Gervasio A. Lamas et al3 1997 727 LV ventriculography 19.4 Present study 2013 119
Echo 22.7 2D EF was found to correlate linearly with 3D EF irrespective of type of STEMI. In a recently
published metanalysis, Jennifer L. Dorosz et al96 showed similar results. With EF, there is no difference in
the bias between 3DE and 2DE, and the difference in the variance is modest (± 4.7%). Despite being
subjected to errors due to foreshortening, poor endocardial definition, narrow echocardiographic windows,
and assumptions about LV shape, it remains a ubiquitous tool for assessing LV size and systolic function in
day to day clinical practise. Although 3DE shows promise in providing the accessibility of echocardiography
and the multi- planar imaging of CMR, this nascent technology still has limited spatial and temporal
resolution compared with gold standard modality of CMR. Despite its limitations, 3DE may be superior to
2D techniques. Our single centre study shades light on the prevalence of Mitral Regurgitation in acute
STEMI in Indian population. MI is most prevalent in middle age persons with ischaemic Mitral Regurgitation
in slightly older age group. Modalities of revascularisation (mechanical vs thrombolytic or medical treatment
doesn’t influence the course of Mitral Regurgitation in short term follow up. However, these findings need
to be confirmed in larger study population MI. STUDY LIMITATIONS The main limitation of this study was
smaller sample size, which was not powered enough to study the predictors of development of MR in
STEMI patients. Moreover, females were underrepresented in the study group, which may have negated
the gender effect on ischemic MR. Critically ill patients , cardiogenic shock etc were not included in whom
,there is a probability of having severe mechanical complications of STEMI like severe MR. There was a
significant drop out during follow up, which may have influenced the statistical analysis. Only
echocardiographic LV systolic function measurements were used and were not compared with other
imaging modalities like MRI, which is gold standard for determining EF in patients with regional wall motion
abnormalities. Longer follow up periods are required for assessing the development of chronic ischaemic
MR. CONCLUSION STEMI patients have 22.7% prevalence of MR at onset, which is more likely in older
age group, diabetics and IWMI patients and independent of gender and left ventricle systolic dysfunction.
Despite under-representation of females in our study population, they seem to carry higher risk of
development of ischaemic Mitral Regurgitation in India. Most commonly, ischaemic MR is of milder severity
at onset which tends to persist in 15.7% of patients during follow up. There is a significant association of
development of ischaemic MR during acute STEMI with IWMI. Some patients may develop new MR later on
depending on the LV remodelling. 2D EF estimation with a properly acquired good image is comparable to
more precise 3D EF in STEMI patients. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53
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INTRODUCTION MR is a frequent complication of coronary artery disease. It was often under-rated
because it is clinically silent, but with the use of echocardiography this complication is observed
between 15%-20% after a myocardial infarction.1 When compared with patients without MR, the
patients with acute myocardial infarction and mitral regurgitation are older, more often in female and
frequently have a history of previous ischaemic heart disease.2 Its presence and degree have major
prognostic implications and underscore the importance of its detection and quantification. Ischaemic
mitral regurgitation can independently predict cardiovascular death with a relative risk of 2.3 In a...
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